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Abstract 
Background: Mental health recovery narratives have been defined as first-person lived 
experience accounts of recovery from mental health problems, which refer to events or 
actions over a period of time, and which include elements of adversity or struggle, and also 
self-defined strengths, successes, or survival. They are readily available in invariant 
recorded form, including as text, audio or video. Previous studies have provided evidence 
that receiving recorded recovery narratives can provide benefits to recipients.  
This protocol describes three pragmatic trials that will be conducted by the Narrative 
Experiences Online (NEON) study using the NEON Intervention, a web-application that 
delivers recorded recovery narratives to its users. The aim of the NEON Trial is to 
understand whether receiving online recorded recovery narratives through the NEON 
Intervention benefits people with experience of psychosis. The aim of the NEON-O and 
NEON-C trials is to evaluate the feasibility of conducting a definitive trial of the use of the 
NEON Intervention with people experiencing non-psychosis mental health problems and 
who care for others experiencing mental health problems respectively.  
Methods: The NEON Trial will recruit 683 participants with experience of psychosis. The 
NEON-O Trial will recruit at least 100 participants with experience of non-psychosis mental 
health problems. The NEON-C Trial will recruit at least 100 participants with experience of 
caring for others who have experienced mental health problems. In all three trials, 
participants will be randomly allocated into one of two arms. Intervention arm participants will 
receive treatment as usual plus immediate access to the NEON Intervention for one year. 
Control arm participants will receive treatment as usual plus access to the NEON 
Intervention after one year. All participants will complete demographics and outcome 
measures at baseline, 1 weeks, 12 weeks and 52 weeks. For the NEON Trial, the primary 
outcome measure is the Manchester Short Assessment of Quality of Life at 52 weeks, and 
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secondary outcome measures are CORE-10, Herth Hope index, Mental Health Confidence 
Scale and Meaning in Life questionnaire. A cost-effectiveness analysis will be conducted 
using data collected through the EQ5D-5L and the Client Services Receipt Inventory.  
Discussion: NEON Trial analyses will establish both effectiveness and cost-effectiveness of 
the NEON Intervention for people with experience of psychosis, and hence inform future 
clinical recommendations for this population.  
Trial registration: All trials were prospectively registered with ISRCTN. NEON Trial: 
ISRCTN11152837, registered 13 August 2018, http://www.isrctn.com/ISRCTN11152837. 
NEON-C Trial: ISRCTN76355273, registered 9 January 2020, 
http://www.isrctn.com/ISRCTN76355273. NEON-O Trial: ISRCTN63197153, registered 9 
January 2020, http://www.isrctn.com/ISRCTN63197153.  
Keywords 
Randomised controlled trial; Pragmatic trial; Recovery narratives; Recovery stories; Quality 
of life; MANSA; Psychosis; Carers; Mental health. 
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Background 
Mental health recovery narratives have been defined as first-person lived experience 
accounts of recovery from mental health problems, which refer to events or actions over a 
period of time, and which include elements of adversity or struggle, and also self-defined 
strengths, successes, or survival (1, 2). They are referred to as recovery narratives in this 
protocol, whilst recognising that this term is used elsewhere in healthcare research and 
practice, e.g. in narratives of recovery after a stroke (3). Recovery narratives can be shared 
live, as part of social interactions with others, or they can be presented in recorded form, as 
invariant text, audio or video (4). In this protocol, the person telling the story, in either form, is 
referred to as the narrator, and the person reading, watching, listening to or otherwise 
engaging with the story is referred to as the recipient (5). 
Sharing of recovery narratives is common (6, 7). Informal peer support, involving interactions 
between individuals with similar experiences of health problems is one example of a 
naturally occurring relationship in which live recovery narratives can be narrated and 
received. Informal peer support can take place in-person (8) or on-line (9). In this century a 
new employment role of peer support worker or peer specialist has emerged in mental 
health systems internationally (10), which involves employing people in roles for which 
personal experience of mental health problems and recovery is a requirement. Intentional 
peer support has an empirical evidence base (11) and is being implemented globally (12). A 
USA national survey has identified helping others through the narrating of mental health 
recovery narratives as a feature of the work of peer specialists (13). Peer support workers 
can create change through mechanisms such as role-modelling of individual recovery (14). 
Davidson, Bellamy (15) have argued that the disclosure by a peer worker of their own 
transition to a “hero of their own self-journey” (p.124) can instil hope in others. The growth of 
peer support work means that an increasing number of people living with mental health 
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problems have access to live recovery narratives shared as part of a supportive relationship 
(15). 
Access to recorded narratives is increasing (6, 7). Substantial numbers of recorded recovery 
narratives are publicly available, distributed through mechanisms including books (16, 17), 
health service booklets (18), on-line collections (19) and digital media hosting services (20). 
Creating narratives can provide benefits for narrators (21), who might be motivated by 
sending messages of “hope, courage and survival” (p. 68) (22), a form of indirect emotional 
support (23). Campaigns which aim to reduce stigma (24, 25), such as Bell Let’s Talk (26), 
have used recorded recovery narratives (27) as a mechanism for creating social contact 
between people with experience of mental health problems and others, drawing on long-
standing evidence for social contact as an anti-stigma mechanism (28, 29). Health material 
shared in anti-stigma campaigns can have a beneficial impact on help-seeking behaviour 
(30), a finding that is important when systematic review evidence shows that stigma can 
disrupt help-seeking behaviour (31). Receiving a recovery narrative can provide personal 
inspiration (32), increase empathy and understanding (33), validate difficult personal 
experiences (34), or provide alternative forms of companionship at times of social isolation 
(35). Receiving recovery narratives can also contribute to recipient distress, e.g. if the 
recipient feels angry or “out of place” through a perception that they have experienced 
greater hardship than a narrator (32). 
The public availability of an increasing number of recorded recovery narratives is an 
opportunity to provide support to people through a new form of mental health intervention. 
Organisations such as Here to Help (36) and the Scottish Recovery Network (37) have 
already created on-line collections of recovery narratives with the explicit intent of supporting 
recovery in recipients. These might be seen as a specific initiative within a larger effort to 
incorporate Digital Healthcare Technologies (DHTs) into mental health practice, motivated 
by known global challenges such as lengthy waiting lists for treatment (38), limited access to 
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in-person mental health treatment in rural and remote communities (39-41), and the distress 
inherent in accessing in-person treatment for people experiencing social anxiety (42). 
Systematic review evidence shows that DHTs can be effective at supporting self-
management for long-term conditions (43), and because face-to-face contacts account for 
nearly 90% of healthcare interactions (44) then developing self-management skills might 
save health service resources, as well as supporting better long-term outcomes (45) 
A recent qualitative study using semi-structured interviews to investigate the impact of 
receiving live and recorded mental health recovery narratives for 77 participants identified 
three benefits specifically attributable to the supportive process of receiving recorded 
recovery narratives: obtaining access to narrators not available in everyday life, having 
control over when and how to access a narrative, and a lack of social interaction burden 
around receiving the narrative (5). The same study presented a change model in which 
impact begins with the recipient connecting to events in the narrative or to characteristics of 
the narrator. Impact was reduced if the recipient is experiencing a crisis, and is positively 
moderated by the perceived authenticity of the narrative. Receiving recovery narratives 
created cognitive and affective change in perceptions of connectedness, validation, hope 
and optimism, empowerment, appreciation, reference shift and reduction in self-stigma. The 
definition of appreciation encompassed a subset of experiences identified as “meaning in 
life” in a systematic review on recovery processes (46). Feeling empowered led to helpful 
behavioural changes emulating those of the narrator, such as increased likelihood of 
disclosure of mental health experiences to others and greater ability to exert control during 
interactions with mental health workers. Harmful transdiagnostic forms of cognitive and 
affective change can also be created by receiving recovery narratives. These include 
perceptions of inadequacy, disconnection, pessimism and burden. Interventions utilising 
recovery narratives should consider how to manage and ameliorate harmful change (5). 
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A recent qualitative study (47) has refined the mechanism of connection presented in (46). It 
has identified three factors underpinning connection: comparison of self to narrator or 
narrative, feeling empathy for the narrator, and learning something from the narrative.  
A recent systematic review (4) provides additional specific items of knowledge that 
complement these two qualitative studies, which post-date the review. It found that recent 
traumatic events disrupt connection to a narrator or narrative, and hence reduce potential 
impact. Receiving the recovery narratives of people experiencing eating disorders can cause 
diagnostically-specific harmful behavioural responses in those with prior experience of eating 
disorders, in the form of emulating harmful behaviours described by a narrator, especially if 
the matched behaviours had been previously enacted by a recipient. Emulation of narrator 
behaviours was initiated by the elements of eating disorder recovery narratives that 
described adversity or struggle. It was potentiated by any specific detail about eating 
disorder behaviours taking place during these periods, such as narrator estimates of how 
many calories they were consuming. 
The above evidence is primarily transdiagnostic, since recovery is a multi-component 
process which is not diagnosis-specific (46). However, there is specific evidence that 
indicates possible benefits of recorded recovery narratives in relation to people living with 
psychosis. An Australian study identified benefits from recorded recovery narratives in three 
domains: being inspired, knowing I’m not alone and believing recovery is possible (34). 
Recovery narratives can create hope, and messages that create hope are known to be 
recovery-promoting in psychosis (48), feeling more hopeful can support recovery through re-
imagining the self (49), and hope mediates potential psychosis recovery indicators such as 
increases in structured activity (50). People experiencing psychosis regularly use digital 
technologies such as social networks (51). Furthermore a systematic review of interventions 
for psychosis incorporating online, social media and mobile technologies concluded that 
these approaches are acceptable, feasible and have the potential to improve outcome (52).  
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No prior Randomised Controlled Trial (RCT) on the use of recorded recovery narratives to 
provide benefits for people experiencing psychosis has been conducted, and an RCT would 
inform the development of diagnostically-specific clinical guidelines for the use of recovery 
narratives with this population. We will conduct a definitive pragmatic (53) RCT (the NEON 
Trial), which incorporates an economic and process evaluation. Recovery narratives, and all 
trial procedures (including randomisation) will be delivered online, through the NEON 
Intervention, a non-medical online interface designed with the intent of supporting people 
experiencing a wide range of mental health problems. The NEON Intervention provides a 
variety of mechanisms for accessing the NEON Collection of recovery narratives. These 
include the use of a hybrid recommender system (54), which uses both collaborative filtering 
(55) and content-based filtering (56) to generate automated recommendations of recovery 
narratives, tailored to information collected about participants. The content-based portion of 
the recommender system uses a model trained using supervised machine learning (57) to 
identify content that might provide benefits for a user.  
In addition to people living with mental health problems, recovery narratives may be relevant 
to their informal carers, such as family members, friends, neighbours and other unpaid 
supporters. Many carers struggle with feeling pessimistic about the possibility of recovery for 
their loved ones (58), and there is evidence that being more ‘recovery-aware’ gives informal 
carers more hope and optimism about the future (59). Established recovery frameworks are 
also relevant to the experiences of informal carers, supporting processes such as 
maintaining hope, reconnecting, overcoming secondary trauma and (for family members) 
journeying from carer to family (60). Although the knowledge base is less developed than for 
people with mental health problems, current evidence suggests that recovery narratives may 
also be beneficial to informal carers. As such, we will use the same digital infrastructure to 
conduct an exploratory study of the use of NEON Intervention for informal carers (the 
NEON-C Trial), to inform the design of a future definitive RCT. Given the transdiagnostic 
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benefits of recovery narratives identified above, we will also run a second exploratory study 
with people with non-psychosis mental health problems (the NEON-O Trial).  
Study aims and objectives 
NEON Trial 
The aim of the NEON Trial is to understand whether receiving online recorded recovery 
narratives benefits people with experience of psychosis.  
The NEON Trial has the following objectives: 
Primary objective 
The primary objective is to evaluate the effectiveness of the NEON Intervention in improving 
quality of life at 1 year follow-up.  
The primary hypothesis is that compared to control group participants not receiving the 
NEON intervention during that year, intervention group participants who receive the NEON 
intervention will have a clinically-important increase in quality of life one year later. Control 
group participants will continue to receive usual care, which has been described as the 
“comparator of choice” (p.92) (61) for pragmatic trials  
Secondary objectives 
1) to evaluate effectiveness in improving hope, empowerment, meaning in life, and 
reducing symptomatology  
2) to evaluate the cost-effectiveness of the intervention compared with treatment as usual, 
from both a health and social care provider, and a societal perspective. 
3) to understand how the intervention is used and experienced  
4) to evaluate the trial change model 
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5) to evaluate the performance of the supervised machine-learning algorithm in producing a 
model that matches recovery narrative content to participants 
6) to understand how the model trained by the machine-learning algorithm develops 
through the trial  
7) to determine whether the effectiveness of the NEON intervention varies according to 
prior health-service usage by a participant. 
Exploratory objectives 
1) to identify potential predictors of outcome, to inform the design and analysis of future 
trials 
2) to examine how the effect of the intervention varies over time and by dose 
NEON-O and NEON-C trials 
The aim of both exploratory trials (NEON-O and NEON-C) is to develop knowledge to 
support the design of a future definitive trial with the target population.  
The objectives are: 
1) to optimise the intervention to the target population, by using usage data to understand 
patterns of dose and adherence, in order to identify candidate refinements to the 
intervention 
2) to optimise the evaluation to the target population, including informing the choice of 
primary and secondary outcome measures in a future trial 
3) to establish trial parameters relating to the target population, by evaluating recruitment 
procedures, estimating recruitment rates, and making a preliminary estimate of effect 
size to inform a future power calculation 
4) to evaluate the performance of the supervised machine-learning algorithm in producing a 
model that matches recovery narrative content to participants 
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5) to understand how the model trained by the machine-learning algorithm develops 
through the trial 
6) to understand the acceptability of the intervention to the target population 
 
The design decisions outlined in this protocol have been optimised for the NEON Trial. 
Aspects of design which differ in NEON-O and NEON-C are identified. 
Study framework for evaluation 
The Evidence Standards Framework for Digital Health Technologies (62) has been used as 
a guiding framework for evaluating the effectiveness of the NEON Intervention. Within this 
framework, the NEON Intervention is categorised as a tier 3a DHT, intended to enable 
preventative behaviour change or allow self-management of a diagnosed condition. A 
feasibility study has provided observational evidence required for tier 3a DHTs (63). All other 
evidential requirements are covered by this trial protocol. 
Study change model for the impact of recorded recovery narratives 
A change model has been synthesised from frameworks developed in a systematic review 
(4) and qualitative study (5). The most empirically supported elements of these frameworks 
were integrated, with priority given to those which can be evaluated in a clinical trial with a 
process evaluation. A specific focus was on the causal chain of intermediate mechanisms 
between intervention and outcome. The change model contains no diagnostically-specific 
elements, and hence is appropriate for use in all three trials described in this protocol. The 
change model is presented in Figure 1.  
Insert Figure 1 here.  
Caption: NEON change model. 
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Initiation of help-seeking behaviours is included as a helpful change, due to evidence that 
this can generally be produced through exposure to mental health material used in anti-
stigma campaigns (30), though no evidence is as yet present that links initiation of help-
seeking behaviours to receiving recovery narratives specifically.  
The change model includes emulation of harmful behaviours as a general form of harmful 
change caused by receiving recovery narratives. Whilst existing research evidence for this is 
limited to recipients with prior experience of eating disorders, receiving on-line material 
featuring self-harm is known to have the capacity to potentiate self-harm (64), and inclusion 
of a more general formulation of harmful behavioural change in the change model enables 
the selection of mechanisms to manage it. As such, this inclusion is justifiable on the 
biomedical principal of non-maleficence (65).  
Methods 
The NEON Trial is a randomised controlled trial, with an internal pilot and an economic and 
process evaluation, and with all study procedures other than process evaluation interviews 
conducted online. The internal pilot sample will comprise participants recruited during the 
first 3 months of the trial, with trial recruiting continuing thereafter. NEON Trial participants 
who meet inclusion criteria will be individually randomised into one of two treatment groups 
(control group, intervention group) with an allocation ratio of 1:1.  
Follow-up is at one week, 12 weeks and 52 weeks after randomisation, with the primary end 
point at 52 weeks. Cost-effectiveness of the NEON Intervention will be established by 
calculating the costs of delivering the NEON Intervention, the impact on services costs of 
receiving the intervention, and the change in QALYs due to receiving the intervention.  
The NEON-C and NEON-O exploratory trials are randomised controlled trials with a limited 
process evaluation. Participants who meet inclusion criteria will be individually randomised 
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into one of two treatment groups (control group, intervention group) with an allocation ratio of 
1:1. The same outcome data will be collected as for the NEON Trial, at the same time points, 
but only exploratory clinical and economic analyses will be conducted. As for the NEON 
Trial, all study procedures other than process evaluation interviews are conducted online. Up 
to 20 semi-structured interviews will be conducted for the process evaluation in each of the 
NEON-C and NEON-O Trials. 
Participant will not be blinded to allocation status in any of the three NEON trials. There will 
be no exclusions based on current treatment.  
The schedule of enrolment activities, interventions and assessments is in figure 2.  
Insert Figure 2 here.  
Caption: Schedule of enrolment, interventions and assessments for all three trials  
Assessments at 1, 12 and 52 weeks are required for clinical and economic analyses. The 
assessment at 104 weeks is not required as only early recruits will reach this before the 
study end date. Participation in interviews for the internal pilot and process evaluation is 
optional and not included in the figure.   
Population 
The study population for the three trials are defined by the following criteria. All are self-
rated, using a shared online interface. Details are provided in the study procedure on 
Eligibility. No formal thresholds will be applied for language comprehension.  
Participants will only be allowed to take part in one of the trials. Where participants meet the 
inclusion criteria for more than one trial, exclusion criteria have been included to specify that 
the order of preference is NEON Trial followed by NEON-O Trial followed by NEON-C Trial. 
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The NEON Trial 
Inclusion criteria 
1. Experience of psychosis in the last five years  
2. Experience of mental health-related distress in previous 6 months 
3. Resident in England 
4. Aged 18 or above 
5. Capable of accessing or being supported to access the internet, either on a personal 
computer, mobile device or at a community venue 
6. Able to understand written and spoken English 
7. Capable of providing online informed consent 
The NEON-O exploratory trial 
Inclusion criteria 
1. Experience of mental health problem other than psychosis in the last five years 
2. Experience of mental health-related distress in previous 6 months 
3. Resident in England 
4. Aged 18 or above 
5. Capable of accessing or being supported to access the internet, either on a personal 
computer, mobile device or at a community venue 
6. Able to understand written and spoken English 
7. Capable of providing online informed consent 
Exclusion criteria 
1. Eligible for the NEON Trial 
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The NEON-C exploratory trial 
Inclusion criteria 
1. Experience of being an informal carer for someone with experience of mental health 
problems within the last five years 
2. Resident in England 
3. Aged 18 or above 
4. Capable of accessing or being supported to access the internet, either on a personal 
computer, mobile device or at a community venue 
5. Able to understand written and spoken English 
6. Capable of providing online informed consent 
Exclusion criteria 
1. Eligible for the NEON Trial 
2. Eligible for the NEON-O Trial 
Interventions 
Control group 
In all three trials, participants allocated to the control group will have no changes to any 
treatment they may be receiving.  
For the NEON Trial and NEON-O Trials, participants will include: 
(1) people currently receiving no mental health treatment 
(2) people receiving primary care mental health treatment, such as pharmacotherapy from 
their family doctor / general practitioner (GP) or counselling from a primary care 
counsellor 
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(3) people receiving support from the Improving Access to Psychological Therapies (IAPT), 
which provides evidence-based psychological therapies and routine outcome monitoring 
to people living with common mental disorders such as anxiety and depression, with an 
increasing availability of services for people living with psychosis and other severe 
mental illnesses (66) 
(4) people receiving treatment from secondary mental health services, such as locality-
based mental health teams or hospital-based services. In secondary care, treatment 
typically involves multidisciplinary care co-ordination under the Care Programme 
Approach (67), a national framework for care co-ordination and resource allocation in 
mental health care whose key features include systematic arrangements for assessing 
health and social needs, formation of a care plan identifying the health and social care 
required from a variety of providers, appointment of a key worker to monitor and co-
ordinate care, and regular review of the care plan.  
For the NEON-C Trial, participants will not currently be experiencing mental health problems, 
as otherwise they would be eligible to participate in the NEON Trial or NEON-O Trial. 
Participants allocated to the control group in all three trials will receive access to the NEON 
Intervention after 52 weeks, for at least one month, or until the trial closes, whichever is later. 
During this period, logging data will be collected on their usage of the intervention. 
Intervention group 
For all three trials, participants randomised to the intervention group will continue to receive 
their usual care (if any). Typical offerings are as has been described for the control group. 
The intervention group will also receive immediate access to the NEON Intervention. 
The NEON Intervention is a password-controlled, online interface which presents mental 
health recovery narratives sourced either from existing public collections such as books, 
health-service booklets and on-line collections, or donated specifically to the NEON study by 
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individuals. Narratives are managed in line with a protocol previously approved by the HRA 
(IRAS: 247343, REC reference: 18/LO/0991).  
The NEON Intervention is accessed through a web-browser, either on a mobile phone or on 
a laptop or desktop computer. It provides four routes to accessing recovery narratives which 
are described below, one of which uses an algorithm to match narratives to participants. This 
is referred to as the matching algorithm in the remainder of this protocol. Information about 
participants used to generate matches is referred to as matching data, and is stored in a 
personal profile, along with other forms of personal information needed by the NEON 
intervention. Information stored in the personal profile is detailed in Additional File 1.  All 
items in the personal profile are considered to be research data. Titles or categories used to 
display personal profile contents to participants may be updated (for example in response to 
feedback collected through the internal pilot).   
The NEON study Lived Experience Advisory Panel (LEAP), consisting of 10 members with 
personal experience of mental health problems, have advised that participants should be 
able to provide as little or as much information in their personal profile as they wish, and 
hence we have minimised mandatory items in the personal profile. Although there is some 
overlap with the demographics form used by the NEON trials, the contents of the personal 
profile are not auto-populated from the demographics form. This is to maintain a separation 
between trial procedures and intervention usage. The exception is contact details provided 
through the consent form, which are essential for operation of the NEON Intervention. Here, 
the personal profile will be auto-populated to reduce participant burden.  
After signing in to the NEON Intervention for the first time, the participant is sequentially 
shown a number of introductory pages intended to facilitate them in learning how to work 
with the NEON Intervention, and to collect enough information for the NEON Intervention to 
function effectively. These pages will not appear on subsequent logins. First interactions with 
a mental health technology are known to present particular difficulties for users experiencing 
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mental health problems (68), and hence these pages have been designed to help a new 
user to rapidly acclimatise to the NEON Intervention.  
The introductory pages appear in the following sequence: 
‘Welcome’ page 
This provide a brief overview of how to use the NEON intervention, seek to normalise 
emotional responses to recovery narratives, and provide initial guidance on how to deal with 
difficult emotional responses.  
‘Initial information’ page 
The Initial Information page allows the participant to provide an initial set of entries for all 
“directly editable” items in their personal profile (see Additional File 1).  To support 
participants in managing their own safety, this includes a list of types of narrative content 
that they wish to hide, using a typology of content warnings developed by the NEON study.  
Some participants will be experiencing conditions that disrupt processing of particular 
formats of narrative, e.g. text-based narratives in the case dyslexia. Some participants may 
have to use public computers to access the NEON Intervention, and hence may wish to 
avoid formats of narrative that include audio. As such, users can select formats of narrative 
that they do not wish to receive. The NEON Intervention interface will not allow the user to 
block all formats, as then they would not be able to receive any narratives.  
The Initial information page will include text indicating that personal profile contents can 
always be updated through the “About me” button during future usage of the intervention.  
‘First story’ page 
This provides a first experience of receiving a short narrative, so that the user experiences 
this as early as possible in their usage. A short narrative will be displayed on this page. Only 
narratives that do not have content warnings will be considered in scope for selection so as 
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to minimize chances of distress. The selected narrative will not be of a format blocked by the 
user, and hence some users will receive different “first stories”.  
After receiving this narrative, the participant will be asked to rate it for hope, and optionally 
four types of connection mechanism, with the following questions and anchor points used, 
and with indicated questions numbers and numerical ranges not visible to participants.  
(Mandatory) 
Q1: How hopeful did the story leave you feeling? [range -1 to 2] 
Less hopeful than before - No change - A bit more hopeful - Much more hopeful 
(Optional) 
Q2: How similar was the story-teller to you? [range 0 to 3] 
Not at all  - A bit - Quite a lot - Very much.  
Q3: How similar was the story-teller’s life to your life? [range 0 to 3] 
Not at all  - A bit - Quite a lot - Very much.  
Q4: How much did you learn from the story? [range 0 to 3] 
Nothing - A bit - Quite a lot – A huge amount.  
Q5: How emotionally connected did you feel with the story? [range 0 to 3] 
Not at all  - A bit  - Quite a lot – A huge amount.  
Q2 and Q3 have been selected to operationalise the connection mechanism referred to as 
“Self-to-other comparison” in the trial change model (Figure 1). Q4 operationalises the 
connection mechanism referred to as “learning”. Q5 operationalises the connection 
mechanism referred to as “empathy”. Responses to these five questions are referred to as 
narrative feedback in the remainder of this protocol, and will be used as matching data. The 
NEON Intervention will encourage participants to provide narrative feedback after each 
narrative received through usage of the NEON Intervention, through it is not technically 
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possible to enforce this, since a participant can always close their web-browser if they do not 
wish to provide feedback.  
The pool of narratives considered in scope for usage as the first story will be reviewed 
approximately every three months after trial start. Drawing on all narrative feedback provided 
by trial participants up to that point, a small number of narratives will be selected which have 
received hope ratings with a high mean and small standard deviation, as these are most 
likely to be beneficial. 
LEAP have advised that participants should be able to block any story, at any point (e.g. 
whilst part-way through reading or watching it), for example if they found it excessively 
distressing. LEAP have also advised that recipients should be able to bookmark a story e.g. 
to allow an influential story to be re-visited, or discussed with a support worker. As such, 
buttons to block and bookmarked stories will be provided on the same screen as the first 
story, and all other subsequently accessed stories.  
After viewing the first story and providing narrative feedback, the participant is given access 
to the intervention home page. This presents four buttons in an ordered list, allowing 
participants to access recovery narratives in different ways: 
‘Match me to a story (recommended)’ button: requests the automated recommendation of 
narratives matched to the participant, presented as a list of stories. This will be the 
recommended approach to narrative selection, and hence appears first in the list. The 
participant can choose to receive just one narrative, or can examine all in the list. The list will 
only include narratives not seen before.  
‘Get me a random story’ button: requests a randomly-selected narrative that they have not 
seen before, using an algorithmic pseudo-random number generator. 
‘Browse stories’ button: shows available narratives grouped by tags, so that the participant 
can browse them. For example, the database may contain 245 narratives which relate to 
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employment. The participant can narrow their search by selecting multiple tags, and the 
participant can choose from narratives matching selected tags.  
‘My stories’ button: shows a list of recovery narratives previously received, unless they 
have been blocked in which case they will not appear. These are presented in two groups: 1. 
Narratives previously bookmarked by the participant 2. Hopeful stories (those rated highest 
for hope, either as indicated by the participant or by the cohort as a whole). The participant 
can select a bookmarked or hopeful narrative to be re-received.  
The Home page also contains a button labelled ‘About Me’. Clicking this button opens a 
page allowing the participant to update any information in their personal profile marked as 
“directly editable” in Additional File 1. It contains a link to a safety event reporting form, in 
case the participant has experienced a Serious Adverse Event, and also a function to allow 
participants to unblock all blocked narratives. Since even the titles of narratives might be 
distressing in some circumstances, then this function will not display a list of all narratives 
that have been blocked, and will instead just summarise the number of blocked narratives.  
To enable easy navigation, the footer of the NEON Intervention, which is always available 
regardless of which page is selected, will contain five buttons: Home, Welcome, About 
NEON, I’m Upset, Get me out of here.  
Clicking these buttons causes the following actions: 
‘Home’ button: takes the user straight to the intervention home page.  
‘Welcome’ button: displays information previously provided on the ‘Welcome’ and ‘Useful 
Information’ pages. 
‘About NEON’ button: opens a page giving more detailed information about the NEON 
intervention, including aims, how narratives were collected, how to make best use of the 
intervention, information about the funders, information about the study team (including a link 
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to the study website http://researchintorecovery.com/neon), functionality to view the consent 
form, and functionality to initiate a withdrawal from the trial.  
‘I’m upset’ button: opens a page giving information about dealing with difficult emotional 
responses. This will remind participants of any self-management strategies they have 
identified. It will suggest common self-management strategies that might help them. It will 
provide links to organisations and services that can be accessed by participants, including 
charities and statutory health services. The design of this page has been refined with LEAP.  
‘Get me out of here’ button: Clicking this button immediately closes the NEON Intervention 
web-page, and logs the user out of the NEON Intervention. It immediately takes the user to a 
neutral web-page (http://www.google.co.uk). 
To distinguish the NEON Intervention from processes associated with the trial (e.g. 
information sheets, completion of measures), the NEON Intervention will not be branded with 
study sponsor or research site logos, and it will be presented with a contrasting colour 
scheme. This is to support the ecological validity of the evaluation by creating a visual 
boundary between trial procedures and intervention content.  
Participants can use the NEON Intervention as little or as frequently as they wish, and there 
is no expected pattern of usage. Patterns of usage will be monitored algorithmically. If the 
participant has not used the intervention for one month, then a reminder message (which 
can be opted out of) will be sent through contact mechanisms specified on the “About me” 
page. This will encourage the participant to re-visit the intervention and give an option to 
access online information about dealing with technical problems, such as reminders about 
the log–in procedure. Messages may also be sent when new narratives that might be of 
interest to participants are added, depending on the frequency of narratives being added to 
the database. 
Measures 
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All measures are included in Additional File 2. All outcome measures to be used in the 
clinical outcomes analysis are summarised in Table 1. The same measures and timepoints 
will be used in all three Trials. Responses to items will be collected online, and validation 
rules incorporated into online forms will ensure no missing items.  
Insert table 1 here 
The primary outcome measure for the NEON Trial is quality of life, assessed with the 
Manchester Short Assessment of Quality of Life (MANSA) (69) at baseline and all follow-
ups. MANSA has been successfully used to assess quality of life in individuals with 
psychotic disorders (70, 71) and other forms of mental health problem (72). Only the 12 
items from section 3 of MANSA identified as subjective are used to calculate a score (69). 
This does not alter the standard scoring system for MANSA, which only uses those 12 items. 
The same data is collected in the NEON-O and NEON-C trials. 
Four clinical secondary outcome measures are used in the three trials. The CORE-10 is a 
self-rated measure of mental health distress, which includes 10 items relating to depression, 
anxiety, trauma, functioning and risk to self (73). The Herth Hope Index is a 12-item self-
rated abbreviated version of the Herth Hope Scale (74). The Mental Health Confidence 
Scale is a self-rated measure of self-efficacy among persons dealing with mental disorders 
(75). The Meaning in Life Questionnaire  is a 10-item measure incorporating two subscales: 
1. presence of meaning in life 2. Degree of search for meaning in life (76). All secondary 
outcome measures have been used successfully with individuals experiencing psychotic 
disorders (66, 77-79).  
Two measures are included for use in the health economics analysis for the NEON Trial. 
The EQ5D-5L (80) is a 5-item self-completed measure of health-related quality of life, which 
is used across a broad range of health conditions. The Client Service Receipt Inventory 
(CSRI) is a measure of service use that enables service costs to be estimated, and which 
  
 Page 28 of 89 
 
can be tailored to each study’s requirements (81). A version of the CSRI has been produced 
which collects service use data covering primary care, secondary mental and physical care, 
social care, and time away from usual activity/employment, defined using employment 
categories presented in the genetic mental health version of the full CSRI (82). These have 
been selected as the major cost-drivers of provision for the NEON Trial population. Item 
count has been abridged relative to a typical item count for the CSRI so as to limit total 
burden on participants of completing measures. CSRI completion at baseline will have a 6-
month retrospective period, and CSRI completion at 52 weeks will have a 12-month 
retrospective period. The same data is collected in the NEON-O and NEON-C trials. 
Health economics measures are summarised in Table 2. 
Insert table 2 here 
Opportunistically, the same follow-up data will be collected at 104 weeks for intervention 
group participants who reach this time point, to allow for exploratory analysis of the longer-
term impact of receiving the intervention. Eligible participants will be those who are 
randomised to the intervention group before end of April 2020.  
Power calculation 
The NEON Trial is powered on mean item score for MANSA. The primary endpoint for the 
NEON Trial is a minimally clinically-important difference in mean item score. This is defined 
as an improvement of 1 scale point in 3 out of 12 items at 1-year follow up in the intervention 
group relative to the control group. A total sample size of 683 (approximately 341 
participants per arm) will provide 90% power to detect a minimally clinically-important effect 
size (Cohen’s d) of 0.27, allowing for 20% attrition (SD=0.9 (83), power=0.9, p=0.05). This 
will give an analysable sample of 546 (273 participants per arm).  
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The sample size for the NEON-C and NEON-O trials have been chosen in order to calculate 
preliminary effect size estimates to inform power calculations for future trials. A total pilot 
study sample size of at least 70 has been recommended to estimate the standard deviation 
of a continuous outcome with good precision (84). This rule of thumb has also been shown 
to be sufficient in minimising the overall sample size across the pilot and main trial when 
medium effect sizes are expected (85). Allowing for 20% attrition the target sample size for 
both NEON-C and NEON -O will be at least 88 (44 per arm).  We have decided to use a 
conservative rounded up sample size of at least 100 (50 per arm) to reflect possible 
uncertainty in the attrition level.  
Procedures 
Recruitment 
The planned recruitment period for all three trials is 14 months. The mean recruitment rate 
for the NEON Trial is 49 participants per month.  
Effectiveness studies evaluate treatments in “real-world” conditions (86). Recent 
epidemiological studies have estimated that psychosis experience prevalence in the general 
population ranges from 7% (70) to 13% (71), whilst lifetime rates of psychosis determined 
through contact with services range from 0.2% (narrowly defined criteria) to 0.7% (broadly 
defined) (72), and hence there is a substantial population of people with experience of 
psychosis but no support from statutory services. Recruitment strategies for the NEON Trial 
will be designed to target a purposive sample (87) of the target population, with the sample 
containing a representative spread of experiences of health service support for psychosis 
experiences. Informed by the epidemiological evidence, this will include participants who 
have received no support from health services. The same recruitment methods will be used 
for all three trials, but recruitment effort will be prioritised to the NEON Trial which has the 
largest target sample size. 
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The following recruitment methods will be used to make potential participants aware of the 
three NEON trials: on-line advertising (disseminated on the study website, by email and 
through social media networks), advertising in print media, placement of posters and leaflets 
in health service and community venues and in public places, snowball recruitment, 
recommendation by general practitioners, mental health workers and social workers to 
clients (either in person, or by other communication mechanisms legitimately used by these 
practitioners), direct approach by researchers to individuals who might be interested in the 
study (either in person, or by other communication mechanisms legitimately used by 
researchers to contact potential participants), presentations by the study team, appearances 
of the study team in national media and recommendation by public figures with an interest in 
mental health. Where individuals are to be approached directly, then governance of what is 
considered a legitimate approach will be delegated to research sites. For example, some 
research sites will have systems in place which allow for the management of “consent to 
contact” lists. These can be used to approach potential participants in the three NEON trials 
if they are authorised for use for these trials at the research site.  
Where promotional material is used, then it will vary greatly in length and amount of 
information, e.g. between text used in tweets and text used in posters. We would anticipate 
sending out at least 100 pieces of promotional material, each tailored to a different audience 
and to the current state of the trial. Early on we may send out broadly relevant messages 
and later we may send out messages that are more targeted at under-represented groups.  
Principles to inform the text for all advertising are given in Additional File 3. These principles 
allow for the generation of recruitment material that is coherent and ethically-sound, but 
which can also be updated as our understanding of how to promote the trial develops, for 
example in response to the analysis of the NEON Trial internal pilot. All recruitment material 
generated will conform to these principles. All promotional material will be logged in the Trial 
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Master File (TMF), with date and location of use, to enable the study sponsor to audit it 
against the advertising principles.  
Samples recruitment posters are included in Additional Files 4-7.  The graphic design of 
these will be updated if necessary, and new graphic designs will be submitted to the HRA as 
a non-substantial amendment. Poster will not be localised to research sites.  
All recruitment activity will result in a participant receiving the web address of the splash 
page for the NEON trials. This is a publicly available online interface which can be accessed 
from a public or private computer or from a mobile device. The splash page incorporates a 
link to a login screen for participants who have already enrolled and who have created an 
online account (“If you have a login click here”). It will have a link to a trial information page 
introducing the NEON Trial, NEON-O Trial and NEON-C Trial. This will describe the purpose 
of the trials and explain the process of enrolling, which may not be familiar to some potential 
participants (“If you are new to NEON click here”). It will link to a page to allow people to 
report safety issues (see the section on safety event monitoring for details).  
The trial information page will indicate if any trial has closed due to attaining the required 
participant count. From the trial information page, a potential participant can access an 
eligibility checking interface. The link to the eligibility checking interface will be removed once 
all trials have closed for recruitment, and all recruitment relating to that trial will be withdrawn 
as soon as possible after trial closure.  
Eligibility checking  
To avoid the burden of an ineligible participant engaging in informed consent procedures, 
potential participants will be asked to answer a short series of questions presented in an on-
line interface. The primary purpose of this interface is to establish eligibility for any of the 
three NEON trials. The interface will also capture how the potential participant learned about 
the NEON trials so as to evaluate the effectiveness of different recruitment methods. It will 
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also capture sufficient information to allocate the potential participant to a research site if 
they are found to be eligible for a trial and then choose to complete consent procedures.  
For all three trials, the benefits of clinician-rating of eligibility are out-weighed by the 
significant extra burden on the participant, the likely lower recruitment rate that would result 
(as some potential participants would not wish their clinical team to be contacted), and the 
fact that many potential participants will not be in contact with mental health services.  
The interface used to present online questions will be publicly available. No online account is 
required to access it. No personal data will be stored as a result of interacting with it, as 
potential participants have not given consent at this point in the study procedures. 
Anonymous non-personal data will be stored to enable accurate reporting of trial recruitment 
processes and to inform advertising strategies. Before being presented with questions, 
potential participants will be shown a message, presented in text, which describes the 
purpose of the chosen questions, and which indicates that the potential participant should 
only fill them out if they are interested in taking part in one of the clinical trials. Carefully-
crafted instructions can shape on-line experience, and can support compliance with a 
designer’s intended use for those experience (88). The current text to be used is included in 
Additional File 8.  If needed to support effective use by participants, the text of all messages 
referenced in this protocol will be refined over time, for example based on feedback collected 
during the internal pilot.   
Eligibility-checking and recruitment logging questions 
Whilst all three trials remain open, questions used to assess eligibility and log information 
about the recruitment process are shown in Table 3. 
Insert Table 3 here 
Questions 3 to 8 in this table have been discussed with LEAP, and the text of these 
questions has been updated according to their recommendations. Questions that relate to 
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mental health have been designed to be accessible to people who have never received a 
formal diagnosis of any mental health condition.  
The flow of questions in the eligibility checking interface will change as trials are closed for 
recruitment, e.g. if the NEON-C trial had recruited all needed participants then questions 7 
and 8 would be removed. In that circumstance, if a potential participant answered no to all 
items in question 5, they would then be given a message indicating they were ineligible for 
any trial.  
Ability to engage with the eligibility checking interface will be taken as evidence that the 
potential participant is capable of using an online intervention, either supported or 
unsupported. Items used in Q5 were drawn from the Threshold Assessment Grid (TAG), a 
staff-rated measure of the severity of mental illness, for which validity has been established 
(89). The phrase used in Q6 for verifying psychosis experiences in potential participants has 
been developed from an earlier NEON study which successfully recruited 28 participants 
with experience of psychosis but no formal diagnosis (2, 5, 90).  
If a potential participant has entered the eligibility checking interface by clicking on a link in 
an online advert displayed on a website, the identity of the website displaying the advert will 
be logged automatically to support an evaluation of recruitment methods, and Q1 and Q2 will 
be skipped. The potential participant will be allocated to the Nottinghamshire Healthcare 
NHS Foundation Trust research site if they chose to progress through informed consent 
procedures, as all participants recruited through non-NHS routes are recruited to this site. To 
enable this automated process, the web address presented in the online advert will contain a 
parameter identifying the online system which displayed the advert. As an example, a web 
address including a parameter of 15 might indicate an advert displayed on the website of the 
Nottingham University.  
Primary care recruitment for all trials is being managed by primary care teams in the 
nationwide network of Local Clinical Research Networks (LCRNs). Q1 will enable a 
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reasonable assessment of primary care recruitment success, which will be considered in the 
analysis of the internal pilot of the NEON Trial.  
Secondary care recruitment for all trials is being managed by selected mental health trusts in 
England, who are operating as research sites. Q1 and Q2 together will enable a reasonable 
allocation of a participant who learnt about the study through secondary care recruitment. If 
“None of these” is selected for Q2, a potential participant is allocated to the Nottinghamshire 
Healthcare NHS Foundation Trust if they complete informed consent procedures.  
If responses to questions indicate that the potential participant is not eligible for any trials, 
then once the questionnaire has been completed, they will be informed of this, through a 
message designed to reduce the number of people who experiment with responses so as to 
obtain access to the NEON Intervention. Current text is message 2 in Additional File 8.   
If a potential participant is considered eligible for a specific trial, then they will next move into 
informed consent procedures.  
Informed consent procedures 
To ensure that a potential participant is sufficiently informed to provide online consent for 
participation, an online PIS will be provided to people considered eligible to participant in any 
of the three trials. UK Health Research Authority (HRA) guidance confirms that the online 
provision of participant information is acceptable (91). Items in the information sheet will be 
provided in a vertical list, and participants will be able to scroll up and down the list. At the 
end of the PIS, a link will be provided to an Informed Consent Form (ICF). Text and layout 
for the online PIS is presented in Additional File 9 and for the online ICF is presented in 
Additional File 10. The PIS will begin with an invitation to take part in a named trial.  
For some items, brief text with expandable detail has been provided. This was 
recommended by LEAP, who reviewed an earlier version of the PIS. It is consistent with 
emerging evidence that shorter information sheets are more likely to be fully read and more 
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likely to be understood (92), and exploits the opportunity offered by digital presentation to 
allow the potential participant to manage how the relevant information is presented. It also 
takes into account the intrinsically challenging and potentially distressing nature of the first 
point of interaction with a healthcare technology for a person experiencing mental health 
problems (68), and is an attempt to make this first contact as accessible as possible. 
Navigation actions, such as scrolling up and down, or opening and closing further 
information, will be logged anonymously to enable a quantitative evaluation of PIS usage, 
and the use of expandable details will be explored in the process evaluation. Data collected 
anonymously will not be linked to the account created for a participant who has completed all 
consent procedures. The exception will be the research site to which they should be 
allocated, which is inferred from questions 1 and questions 2.  
The PIS and ICF will contain contact details for the NEON research team. Potential 
participants will be encouraged to contact the team if they have any questions not answered 
on the PIS. After reading the PIS, a potential participant will be provided with two buttons, 
labelled “I do wish to take part in the trial” and “I do not wish to take part in the trial”. 
Participant choice will be logged anonymously, to allow for accurate reporting of the trial. For 
participants who do not wish to participate, this message will be displayed: 
Thank you for considering involvement. If you change your mind you are welcome to 
return and re-register. You can safely close this window. 
Participants who select the “I do wish to take part in the trial” button will be asked to 
complete the online consent form. A joint statement of the HRA and the Medicines and 
Healthcare products Regulatory Agency (MHRA) on seeking consent by electronic methods 
(93) indicates that online consent is acceptable for all studies other than Clinical Trials of 
Investigatory Medicinal Products (CTIMPs).  
A key advantage of an online intervention is that participants can use a system anonymously 
if wanted. This feature is particularly relevant to the population for the NEON Trial, since 
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people with psychosis may be particularly vulnerable to concerns about online data usage 
and may also fear stigmatisation due to mental ill-health (94). There is evidence that the 
option to remain anonymous influences decisions about use of online interventions by 
people with psychosis (95). The option to remain anonymous has been successfully used in 
a number of online interventions with this population (96) (97). Therefore, the person will 
only be required to check each box on the consent form, rather than providing potentially 
identifying information such as a signature. This is in keeping with procedures specifically 
described and allowed in (93). However, as a minimum, potential participants must provide a 
valid email address, so as to enable the collection of online outcome data. Participants who 
wish to remain anonymous can use email addresses that do not include their name.  
To consent to take part in the study, the potential participant must supply all mandatory 
information required by the ICF, which includes providing a valid email address. They are 
then provided with two buttons labelled “I agree to take part in the study” or “I do not wish to 
take part”. If they click “I agree to take part in the study”, they will be given a message 
indicating that, to complete the registration process, they need to click on a link in a 
validation email sent to their account. Since a working email address is required for usage of 
the NEON Intervention, then only potential participants who click this link will be enrolled.  
After clicking the link, the potential participant is now enrolled in the study. They will be 
asked for a password of their choosing, as choosing their own password will be easier to 
remember. No password complexity rules will be enforced. The participant will be reminded 
to make a note of login details, and given the option of receiving an automated email or text 
with the web address and their login details. Although sending such a message constitutes a 
potential security risk, this is a population who may have cognitive processing and strategic 
planning deficits. Therefore the risk in this case is out-weighed by the benefits of offering the 
participant the chance to have all information to allow them to use the intervention in one 
place.  
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Participants will not be told of the research site they have been allocated to. This would be 
confusing; as once an individual has confirmed participation then all planned participant 
interactions are either with the NEON Intervention or with the NEON study team.  
Baseline data collection 
At first login, study participants in both groups will be asked to complete baseline measures 
using an online interface. They will be shown a message which explains the purpose of 
completing baseline measures, provides an estimate of how long the task will take, reminds 
them that they can claim a voucher for completing it, and reminds them that measures will 
need to be completed again later in the trial. Some items in baseline measures include 
questions that might be perceived as sensitive, and hence the message recommends that 
the participant finds a private place. Current text is message 4 in Additional File 8. 
Participants in NEON-O and NEON-C will not be offered any payment for completing 
measures, and hence for these trials a modified message will be used which excludes 
information about participant payment.  
Participants will then be asked to complete a demographics form and all measures. Each will 
be presented on a single form, which will start with a title and a single sentence describing 
the form, to support participant comprehension of purpose. All critical information to include 
on forms is summarised in Additional File 2. Demographic items on English national ethnicity 
(98) and on educational attainment (98) have been simplified from those produced by the 
Government Statistical Service guidance on harmonised questions and concepts for social 
data sources. An item on recovery status is included for those participants experiencing 
mental health problems. This incorporates a three-stage model of recovery, which currently 
has the strongest empirical support (99), including through a study which recruited in 
England (100).  
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To minimise data incompleteness, responses will be validated as entered in online forms 
used to collect demographics and measures. For example, a participant will not be able to 
click ‘Next’ until all items on the page have been rated, and can only provide an eligible data 
value. If the web-browser is closed before all items are completed, then participants will be 
required to continue completion at next logon. After submitting a form, if a participant uses 
the “Back” button in their web-browser, then the form will be displayed again with all data 
items entered automatically, and the participant will be able to update the values that have 
been entered and resubmit.  
After completing the final form, the participant will be given a message thanking them for 
their responses, and confirming once again that their data is confidential. The back button 
will no longer take them back to a previous form. NEON Trial participants will be provided 
with a link to claim a £20 voucher as a compensation for the time and effort of completing 
questions. The voucher will be sent using the participant’s registered email address, using 
an electronic voucher service provider. Receiving a voucher is optional, and will always be 
initiated by a participant. A request to be sent a voucher will be logged for study reporting 
purposes. 
In providing payment by voucher, there are two risks to address. One risk is technical error 
in the implementation of the NEON Intervention, which might result in multiple vouchers 
being sent to a participant for a single set of completed measures. The second is deliberate 
fraud, e.g. through a participant registering multiple accounts purely for the reason of 
claiming multiple vouchers. The following management strategies have been selected: 
1. The PIS will indicate that vouchers are paid up to one week after a claim is submitted, to 
allow the study to team to investigate and verify unusual patterns of voucher claims.  
2. Each request for a voucher will require the approval of an administrator, who will match 
the voucher request to an available code. This means that no voucher codes need to be 
stored in the NEON Intervention. 
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3. The IP address of the computer used to make a voucher claim will be monitored. For 
each timepoint of the study, no more than 10 vouchers per IP address will be paid. This 
number has been selected to allow for multiple eligible users in the same residence, who 
might have different logins to the NEON Intervention but share an internet connection – 
since domestic routers typically assign the same IP address to all devices connected to 
the router. It will also account for several individuals accessing the NEON Intervention 
from the same public computer (e.g. in a public library).  
4. Unusual patterns such as more than 5 voucher claims in a single day from an IP address 
will be investigated by the study team. The study team will contact relevant participants 
using their registered email address, to gather information about voucher claims, and will 
reserve the right to suspend trial participation and to withhold voucher payment if 
suspicious behaviour is identified. Decisions will be made by the CI, with reasons 
reported to the study sponsor and logged in the TMF. If trial participation is suspended, 
then the participant will not be included in study analyses. 
Randomisation 
Participants will then be randomised to either the intervention group or the control group. 
The intended allocation ratio (intervention group: control group) is 1:1 for all trials. No 
stratification of participants on any baseline covariates will be conducted, as existing 
research does not provide sufficient evidence to reliably identify covariates (101). 
Randomisation will be through permuted block randomisation (102), with randomly varying 
block length. This will use pre-computed listed uploaded by an independent statistician.  
Blinding of participants to allocation status is not possible given the design of the 
interventions. Control group participants will be given a message reminding them that they 
are still an important part of the trial, and that they will receive access to the NEON 
Intervention in one year. Current text is message 5 in Additional File 8. Intervention group 
participants will be told that they will receive immediate access to the NEON Intervention, 
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and asking them not to share their login details with others, to reduce contamination. Current 
text is message 6 in Additional File 8. After receiving this message, intervention group 
participants are then taken to the ‘Welcome’ page, as described in the Intervention section 
above. At future logins, intervention group participants go directly to the intervention home 
page.  
Control group participants are taken to a cut-down version of the Intervention home page, 
which only displays the ‘About NEON’, ‘About Me’ and ‘I’m upset’ buttons. The About Me 
button links to a cut-down version of the About Me page, which only allows for the updating 
of contact information and for participants to open a safety event reporting form.  
Follow-up data collection 
Participants will be asked to complete follow-up measures at the times shown in Table 1 and 
Table 2. A request will be sent using current contact information for the participant, e.g. as 
collected through the online ICF or updated through the “About me” page. The request will 
include a web address that allows the participant to fill out outcome measures. Intervention 
group participants can also be prompted through the NEON Intervention if they log in to it at 
a time point when outcome data can be collected.  
When entering follow-up data the same validation procedures will be used as for baseline 
data collection, and the same payment procedures will be used (i.e. a £20 voucher will be 
offered on completion of measures at each follow-up timepoint). Follow up data will be 
considered valid if provided within two weeks of the one week follow up date, and if provided 
within one month of all other follow-ups. Decisions on how to handle data which falls outside 
of these windows will be detailed in the statistical analysis plan. Incomplete forms will remain 
available up until the start of the next follow-up period. For example, if a participant fails to fill 
out the week 1 MANSA questionnaire, then the questionnaire will remain available at next 
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login up until the start of the week 12 follow-up period, at which point they would receive the 
week 12 MANSA questionnaire. 
At all follow-ups, all participants will be asked to complete a recovery narrative usage 
questionnaire to track contamination. To inform the process and economic evaluation, at 52 
week follow up all intervention group participants will be asked to complete a support 
received questionnaire. Both are detailed in Additional File 2.  
Reviewing consent and initiating withdrawal 
Participants can view their consent form and initiate withdrawal by logging in to their account 
and viewing the “About NEON” page, which is visible to both control group and intervention 
group participants. This page contains a button labelled Consent, which links to a page 
providing options labelled (1) look at the consent form and (2) I wish to withdraw from this 
study. If the participant selects (2), they are shown a message allowing them to either 
confirm their request, ask for a discussion with a NEON researcher, or to cancel their 
request. Current text is message 7 in Additional File 8. If they choose to withdraw, they 
receive message 8, which tells them that all identifiable information has been deleted, and 
tells them how to provide anonymous feedback about the intervention. If they request a 
discussion, they receive message 9, which tells them how a researcher will get in contact 
with them. If they choose to cancel their request, then they are taken to the intervention 
home page.  
End of study participation 
Access to the NEON Intervention must close before the end of the NEON study unless 
alternative funding arrangements are identified. The end of a period of engagement with a 
mental health technology needs to be carefully managed, as it has the potential to be an 
emotionally-charged process, especially if the technology has provided benefits to a user 
(68).  
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To support participants in the NEON trials through the ending of their engagement with the 
NEON Intervention, then a message will be sent no later than a month before a participant 
will lose access. This will thank them for their participation, and inform them of when they will 
lose access (message 10 in Additional File 8).  
Once their participation has concluded, they will be sent message 11 (Additional File 8), 
which will indicate other sources of recovery narratives that they can consult, using a public 
list maintained by the NEON study (103), and intended to remain publicly accessible beyond 
the close of the NEON study.  
Automated data logging 
Logging data will be collected for a range of interactions with NEON interfaces, to support 
accurate reporting of the trial and for use in the clinical and process evaluations. Only 
anonymous data will be logged until consent procedures have been completed. Table 4 
summarises the events logged about potential or enrolled participants. Each event will be 
given a unique name to distinguish it in the log files (e.g. ELIGIBILITY_START for the first 
item in the table). 
Insert table 4 here 
The following terms describe information logged through this process: 
DATETIME: Date and time that an event took place. Minimal recorded accuracy of one 
second 
PPID: Potential participant ID – temporary ID allocated to potential participant so as to 
link data they provide into trial records. Not linked to any identifiable data until consent is 
given.  
How found: Primary care. Secondary care. Online advert [name provider], Other 
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CRN region: North East and North Cumbria, North West Coast, Yorkshire and Humber, 
Greater Manchester, East Midlands, West Midlands, West of England, Thames Valley 
and South Midlands, Eastern, Kent Surrey and Sussex, Wessex, South West Peninsula, 
North Thames, South London, North West London 
Research site: Null, [any of the current secondary care research sites] 
Allocated trial: NEON Trial, NEON-C Trial, NEON-O Trial, Ineligible 
PIS item number: Number of the item being read on the PIS (“1”, “2” etc) 
PIS action:  Scroll up, Scroll down 
PIS item action: Expand, Collapse 
Participation decision: Participate, reject 
Process evaluation participation decision: Yes, no 
PID (Participant IDentifier): The unique ID allocated to each participant after informed 
consent has been given. 
Form name: Demographics, MANSA, CORE-10, Herth, MHCS, MIS, EQ5D, CSRI 
Form items: All items on a demographics or measures form 
NID (Narrative IDentifier): The unique ID allocated to each recovery narrative by the 
NEON study team before uploading to the NEON Intervention. 
RID (Request IDentifier): The unique ID allocated to each recovery narrative request.  
SID (Session IDentifier): The unique ID allocated to each session of usage of the NEON 
Intervention.  
Allocated group: Intervention, control 
Route to access: Content-based match, Collaborative match, Random, Category, 
Hopeful, Bookmarked, First 
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Access device: Mobile device, Computer 
Narrative feedback: As defined in the description of the intervention 
Reminder Communication Mechanism: Email, SMS, Facebook etc 
About Me: A vector of (name,value) pairs representing the set of values entered by the 
participant using the About Me page. 
Button name: About me, I’m upset, Welcome, Get me out of here 
Safety event type: Death, Life threatening event, Hospital admission, Hospital stay 
extension, Disability or incapacitation, Something else 
Caused by study: Yes, Unsure, No 
Date of event: Date that the safety event occurred (but not time) 
Categories: Vector of categories used to narrow down narrative, if category view used to 
find narrative 
Q5 responses: All responses provided to Q5 in the eligibility-testing questionnaire.  
Logs providing information about operation of the online system as a whole and of the 
matching algorithm will also be collected. These are summarised in Table 5.  
Insert Table 5 here 
The following terms describe information logged through these processes 
Parameter list:  A vector of <name,value> pairs describing the model produced by 
retraining 
Narratives: A list of NIDs added to the NEON Intervention  
The “heartbeat” provides a mechanism for understanding whether the online interfaces was 
available for participant use at any given time. It will be recorded at a minimum interval of 
one minute (more regularly if possible within the technical constraints of the web-server 
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hosting the interface). This will be augmented by timestamps of the moment when the 
system restarts for any reason, to one-second accuracy. Because crashes are caused by an 
unanticipated system failure, then it is not technically feasible to record the precise moment 
when an unplanned system close down occurred.  If a planned system close down takes 
place (e.g. for technical maintenance work) then this will be logged to one-second accuracy. 
Addition of new narratives to the NEON Intervention  
New narratives may be added to the NEON Intervention as the trials proceed. This will allow 
for the optimisation of the NEON Intervention. The addition of new narratives would be 
important if interim analyses of demographic data show that participants have joined the 
trials from groups who are under-represented in the NEON Collection. It would also be 
important if some participants used the NEON Intervention so regularly that they were at risk 
of “running out” of new narratives to access. The addition of a batch of new narratives may 
incentivise re-engagement with the NEON Intervention, and prompts might be sent to draw 
attention to the presence of new narratives. If new narratives are added, then they will be 
added in a small number of batches, at intervals of no less than two months. The date and 
contents of each batch will be logged in the statistical analysis plan.  
Operation of the matching algorithm  
The NEON Intervention is a hybrid recommender system (54), which uses both collaborative 
filtering and content-based filtering to match narratives to users. When the user requests a 
new match, the list of narratives presented to the user will include a small number of items 
generated through each route. When narratives in the match are accessed, logging will 
incorporate an item indicating whether accessed narratives were recommended through 
collaborative-filtering or content-based filtering, so that evaluation work can generate 
knowledge on the relative importance of these.   
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Recommendations based on collaborative filtering will identify narratives with characteristics 
which have previously received positive narrative feedback scores from users considered 
similar to the requesting user, using a distance metric (104) calculated from user 
characteristics listed in the personal profile and from narrative feedback scores. 
Recommendations based on content-based filtering will identify narratives whose content is 
predicted to appeal to the requesting user. This prediction will utilise a model developed 
through supervised machine learning (57). 
The supervised training process for this model requires a training data set, and a larger 
training set typically leads to a more effective model. All three trials will start with a single 
model trained from data collected during the intervention development phase of the NEON 
study (63). This means that each trial will start with an identically-parameterised model. This 
model will then be retrained using narrative feedback data provided by participants in each 
of the three trials. The models used in each trial will diverge, which is appropriate given the 
differing study populations. Retraining will take place regularly during the trial to maximise 
the benefits provided by retraining. Retraining will be conducted at least once during the 
internal pilot to assess the technical feasibility of retraining the algorithm whilst the NEON 
Intervention is still in use. At each retraining point, and in line with objective 6, all parameters 
defining the model will be logged, to allow for an understanding of how it has developed. The 
retraining protocol used during the trial will be logged in the statistical analysis plan, and 
included in the trial report.  
The NEON Intervention is intended to support positive psychological change in the user. To 
enable any change to influence the matching process, then at key points, the user may be 
prompted to update user characteristics stored in their personal profile. This is most likely to 
lead to changes in the “Recovery status” or “Diagnosis” item. Prompts might occur 
immediately after filling out follow-up questionnaires at 1 week and 12 week follow-ups. They 
would be sent by any communication mechanism in their personal profile after receiving 
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each batch of 25 narratives. Older narrative feedback scores will be reduced in weight and 
eventually discarded for the purpose of calculating preference similarity with other users in 
collaborative filtering.  This reflects the assumption that psychological change might be 
manifested in changes in narrative feedback behaviour. 
We would anticipate that the effectiveness of the matching algorithm will improve over time. 
Recommendations made by collaborative filtering are likely to improve as new participants 
join the trials, since a larger number of participants may mean a more precise identification 
of others who are similar to the participant requesting a match. Recommendations made by 
content-based filtering are likely to improve as new content is added, as this provides for a 
greater pool of content, and as the model used to match participants to content is refined.  
Qualitative process evaluation data collection 
Qualitative process evaluation data will be collected from the following groups: 
1. The first 30 intervention group participants in the NEON Trial will form an internal pilot 
group. Each will be offered the opportunity to take part in the process evaluation of the 
internal pilot, at least two weeks after randomisation.  
2. Any NEON Trial participants who withdraw their consent for participation (the 
withdrawal of consent group) will be given the opportunity to tell the research team by 
email about how NEON can be improved. As these are no longer participating in the trial, 
they will not be interviewed but simply given the opportunity to provide feedback, which 
will be retained anonymously. Beyond clarifying any ambiguities, dialogue will not be 
entered into following receipt of any feedback, other than to thank the person for their 
feedback. 
3. Intervention group participants for the NEON Trial will be offered the opportunity to take 
part in the process evaluation of the trial at the end of their one-year participation. 
Interviewing will continue with this group until either theoretical saturation or 50 
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interviews have been completed, whichever is sooner. Up to 20 participants in the 
NEON-C and NEON-O trials will be invited to a process evaluation interview.  
4. If attrition is significant from the NEON Trial, interviews with up to 20 intervention group 
participants who only minimally used the intervention (low engagement group) will also 
be conducted, to understand the perspective of people who may not have found the 
intervention useful. 
Participants in the internal pilot, intervention and low engagement groups will be contacted 
using their current contact information, and asked to participate in an interview with a 
researcher by phone or secure video-conference. At the start of the interview, the researcher 
will remind the participant that their participation is voluntary, that their participation in the 
interview will be confidential, and that only anonymised transcripts will be used in analysis. 
They will be asked to confirm that they consent to take part. These conversations will be 
captured in the audio recording of the interview. They will also be recorded onto a paper 
consent form by the researcher [Additional file 11]. In all cases, participants can ask for an 
interview with a peer researcher if preferred. £20 will be offered to all participants as 
compensation for time and effort incurred, payable by electronic voucher or submission of a 
claims forms.  
Interviews with the internal pilot group will focus on assessing the fidelity and safety of the 
intervention. This will allow the Programme Steering Committee (PSC) to make any 
necessary decisions about changes to study procedures following on from the internal pilot. 
The topic guide for internal pilot interviews will include questions intended to identify safety 
issues, to ascertain whether the NEON Intervention has been experienced as intended, and 
to identify factors limiting fidelity, such as technical problems experienced by participants, or 
features of the interface limiting accessibility. Internal pilot interviews will take a maximum of 
1 hour.  
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Interviews with the intervention and low engagement groups will be broader for NEON Trial 
participants. A draft topic guide is shown in Additional File 12. In line with qualitative 
methodologies, the interview schedule will be refined over time.  During the interview, some 
intervention group participants will be shown visualisations of logging data collected by the 
NEON Intervention, and asked to explain interesting or unusual patterns, such as periods of 
very heavy or very light usage. This is a standard approach to enabling reflection on 
computer system usage (105), and provides a mechanism for augmenting system logs with 
the cause of such phenomena. Interviews with the intervention group for the NEON-O Trial 
and NEON-C Trial will be shorter, and will focus on the acceptability of the intervention to 
these participants.   
Resilience to unplanned system downtime 
Occasional unplanned system downtime is to be expected with online interventions. A 2018 
study of 32 web-hosting providers estimated 35 hours downtime per year (106). This makes 
it likely that some participants or potential participants will experience unexpected downtime 
whilst using the NEON Intervention.  
Unexpected downtime might occur before consent has been provided by a potential 
participant. In this scenario, potential participants will need to complete eligibility checking 
processes again. Since no identifying information about potential participants can be 
collected until consent has been provided, then it will not be possible to inform potential 
participants of the need to recomplete eligibility-checking processes.  
Unexpected downtime might occur after consent has been provided, but before 
randomisation has been completed e.g. part way through completing demographics and 
measures forms. In this scenario, a participant can continue completing demographics and 
measures forms next time they log in. Data will be retained from any completed forms and 
will not need to be re-entered. In the event of this scenario, the participant will be sent a 
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reminder of the need to complete demographics and measures, by any contact mechanism 
they have specified on the consent form. This will be sent at least one day after the first form 
was completed.  
Unexpected downtime might occur after a participant has been randomised. This is 
inconsequential for trial processes and hence no specific response is needed.  
Safety event monitoring, response and reporting 
Study principles 
For all three trials, only Serious Adverse Events (SAEs) will be monitored. This study policy 
has been agreed with the PSC and study sponsor. It is consistent with HRA guidance which 
indicates that only SAEs which are unexpected and related to the study should be reported 
to REC (107). It has been informed by the online nature of the trials described in this 
protocol. Since these have no planned routine face-to-face contact with clinical or research 
staff, then this would make routine monitoring for non-serious Adverse Events (AEs) 
intrusive. No event monitoring or reporting will take place after the trial has closed, even if a 
reported event pre-dated the end of the trial.  
The HRA define SAEs (107)  as an untoward occurrence that: 
(a) results in death;  
(b) is life-threatening;  
(c) requires hospitalisation or prolongation of existing hospitalisation;  
(d) results in persistent or significant disability or incapacity;  
(e) consists of a congenital anomaly or birth defect; or 
(f) is otherwise considered medically significant by the investigator. 
The following Adverse Events may result in an SAE and can be reasonably expected from 
this study having been identified from the trial change model presented in Figure 1. As they 
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are expected they will not be reported to REC, in keeping with protocols established for other 
online studies (108). All items in this list are specifically identified in the PIS as a possible 
harm of taking part in the trial so that potential participants can make an informed choice 
about participation. 
 Feeling disconnected from others 
 Feeling more pessimistic 
 Feeling emotionally burdened 
 Feeling inadequate 
 Experiencing the release of uncomfortable emotions 
 Engaging in harmful behaviours encountered in narratives 
In the event of uncertainty about whether an SAE should be categorised as unexpected, the 
CI can ask for a categorisation recommendation from the PSC chair. 
All SAEs, regardless of categorisation, will also be reported in an anonymous form to the 
PSC in case a specific response is indicated, such as a change to trial procedures. If a Data 
Monitoring Committee (DMC) is formed, then the event will be communicated to the DMC 
with all participant details intact.  
Safety event monitoring procedures 
Since these are online trials with no face-to-face contact, then it is likely that the CI will not 
become aware of all SAEs. The following procedures have been selected to create the 
maximum opportunity for SAE reporting: 
 The version of the CSRI used in all three trials includes questions on nights spent in 
hospital and admissions to other hospital-based services. When used in the 12-month 
follow-up assessment, the retrospective period for the abridged CSRI is 12 months, 
which covers the entire duration of participation in the trial. As such, If a number other 
than 0 is entered for any of these questions, then this could indicate that an SAE of type 
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c has occurred, although it is still possible that the hospitalisation was planned, such as 
an operation for a physical health problem. Follow up questions will be asked through the 
online form to collect sufficient details to allow for an event to be identified and 
categorised. Specific questions are included in Additional File 2.  
 The splash page for the NEON Intervention will include a link to an online safety 
reporting form for use by participants or non-participants, which will allow SAEs of all 
types to be reported. Questions included in the safety reporting form are included in 
Additional File 13. After completing the form, the respondent will be given a message 
informing them that the report has been received. The respondent cannot be informed of 
how it will be processed as this would breach the confidentiality of any participant that 
they reported on.  
 The “About me” page will include a link to an online safety reporting form, which allows 
participants to report SAEs (see Additional File 13). After completing the form, the 
respondent will be given a message thanking them for their report. Since this form is only 
accessible to the participant, then it will exclude type a SAEs, as the participant cannot 
complete this form if they have died.  
When an SAE is identified through an online form, then an email notification of the SAE and 
all accompanying information will be sent to the CI and study coordinator. 
Members of the study team or research site teams may also become aware of Adverse 
Events (AEs) through a direct communication from a participant or third party such as a 
family member or clinician. Some of these events may be classifiable as SAEs. Team 
members may become aware of these events: 
 By email or phone, using contact details provided on the PIS, or which are otherwise 
available publicly 
 through discussions in process evaluation interviews 
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Any generic email address or phone number used by the study team will include a message 
indicating how regularly it will be monitored, and indicating that a response will be generated 
by the study team within a maximum of three days.  
Since the study policy is only to monitor SAEs, then the person receiving a communication 
will first assess the event. All individuals who might receive AEs will undertake Good Clinical 
Practice (GCP) training in advance of trial start to support them in understanding how to 
respond and categorise them, and appropriate supervision arrangements will be in place to 
support their practice and safety.  
If the received communication relates to participant difficulties that do not reach the 
threshold for an SAE, then the person sending the communication will be sign-posted to the 
support options identified through the ‘I’m upset’ button, which is available to both the 
Intervention Group and the Control Group. If participant difficulties do reach the threshold for 
an SAE, the communicator will be asked about whether the study contributed to the event, 
and for further details of the event and its cause. The CI and study coordinator will be 
immediately informed of the event and the details that have been collected. If the person 
receiving the communication has any doubt about how to categorise the event, they will 
proceed on the assumption that it is an SAE, and the event will be referred to the CI.  
In all reporting routes, if further information is needed about the event, then the CI or a 
delegate will attempt to contact the respondent for further details. If contact cannot be 
established with the respondent within three days, then the CI will log this, and will make 
decisions based on available information.  
Safety event categorisation and reporting 
The CI will assess all events reported to them, using all available information. If the event is 
categorised as being an SAE that is both unexpected and related to the study, then it will be 
reported to the REC, study sponsor, PSC  and DMC if formed, within 15 days of the CI 
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becoming aware of it. All SAEs will also be reported to the PSC chair, who will decide how to 
respond, in collaboration with the CI. Options include no response, a direct recommendation 
to the CI from the PSC chair, or referral of the SAE to the full PSC or DMC for discussion 
and recommendation.   
Emergency unblinding  
The online interface used by the neon trials will provide a function to reveal the allocation 
status of a single participant based on their ID, so as to enable emergency unblinding. This 
will only be accessible to the CI and study coordinator. Use of this function will be logged for 
the purposes of audit.  
Data handling and record keeping 
Data management 
Electronic trial data will initially be collected through an application running on a secure web-
server, and placing data into a secure database. The application, web-server and database 
will be controlled by DRT Software, an IT supplier with a contractual arrangement to the 
study sponsor to control the data processing operations that can be performed, which will be 
specified in the delegation of duties log. The web-server and database will be hosted by a 
web-hosting provider contracted to DRT Software. The web-hosting provider will be 
accredited an information security standard agreed with the study sponsor in advance of trial 
start (such as Cyber Essentials or ISO27001). The application will not be opened to trial 
participation until the study sponsor has agreed in writing that hosting arrangements meet 
appropriate levels of security for hosting sensitive personal information.  
In the application, information that might identify an individual (e.g. email or phone numbers 
provided through the consent form) will be stored in a separate database from anonymous 
research data, linked only by ID. All information will be encrypted at rest using 256 bit AES 
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encryption or equivalent, or stronger. A backup process will be specified in a data 
management plan agreed with the PCTU, IT supplier and study sponsor, and all backups will 
be encrypted at rest. All information will be encrypted in transmission to and from the server 
using HTTPS. At close of trial, all data stored on the web-server, database and associated 
backups will be deleted, using a thorough deletion protocol. When logging data from the 
trials is copied off the server, then this will be logged so as to reveal who has accessed 
unblinded research data. For analysis and storage until end of the NEON study, anonymous 
research data will be transferred over HTTPS to a research server managed by the 
University of Nottingham.  
The exception to the above arrangements will be qualitative process evaluation interview 
data. Interviews will be carried out by either telephone or secure video conference. 
Recordings of interviews will be made on computers with encrypted hard drives and/or to 
encrypted audio recorders. As soon as possible, data will be copied onto research servers 
managed by the University of Nottingham, and then deleted from the source device.  
All data placed onto University of Nottingham research servers is backed up to two 
geographically-redundant backup systems. Initially, the CI will only delegate access to the 
research team and study sponsor (the latter for the purposes of audit only). The research 
team incorporates staff at the University of Nottingham, PCTU, King’s College London, 
University of Manchester and Queen Mary University of London. If researchers work at sites 
other than the University of Nottingham, then they will be able to download anonymous 
research for analysis using an individual associate account, using a secure file transfer 
protocol. Alternatively, external researchers will be able to access data and analysis 
software using a remote desktop application, working over a secure connection. Consent 
logs will also be transferred to the same research servers, but to a different location, and 
with access initially limited to the Chief Investigator only, and then delegated if necessary 
using the delegation of duties log.  
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All of the above procedures will be approved in writing by the study sponsor before the trial 
opens to participants, and approvals will be deposited in the TMF. The study sponsor will be 
the Data Controller for personal information, and the IT contractor, web-hosting provider and 
University of Nottingham will be data processors. Data processing operations will only be 
entered into once satisfactory contracts are in place to control data processing operations, 
such as collaboration agreements. All processing of personally-identifiable data will be 
logged, in keeping with GDPR requirements.  
Where research data is provided directly by participants, e.g. by completing electronic forms 
presenting items from demographics or outcome measures, then the design of these forms 
will be reviewed by a PCTU-approved statistician before use, and they will not be used to 
collect data until signed off by the statistician. 
Confidentiality 
Procedures for separation of identifying and anonymous data are recorded as above. All 
participation will be confidential. Confidentially will only breached if, following a contact with a 
research team member, the Chief Investigator decides that a participant is at risk to self or 
other, or has committed a notifiable offense. In this circumstance, consent logs will be 
searched for information that can be used to contact the person, and if possible the 
confidentiality breach will be agreed with the participant in advance. If agreement cannot be 
reached, then the Chief Investigator may choose to pass on contact information to a relevant 
statutory authority.  
Record retention and archiving 
The body with responsibility for archiving of records beyond the end of the NEON study is 
Nottinghamshire Healthcare NHS Foundation Trust. For non-CTIMP studies, the funder 
indicates that the sponsor stipulates retention and archiving policies (109) (see sub-page on 
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archiving). The sponsor indicates a minimum retention period of 5 years for all records 
generated by this study.  
Annual reporting 
The CI will also send Annual Progress Reports to the trial REC and the sponsor using the 
HRA template. This will be within 30 days of the anniversary of receiving the REC 
“favourable opinion”. 
Monitoring and auditing 
The Sponsor or delegate retains the right to audit any study, study site or central facility. In 
addition, any part of the study may be audited by the funders where applicable. Audits will 
include the contents of the TMF and ISF (to ensure compliance with SoPs).  
Study committees 
All three trials will be overseen by an independent Programme Steering Committee (PSC), 
who will function as a Trial Steering Committee (TSC). This committee has previously been 
convened by the CI. The chair of the PSC is Professor Sonia Johnson (Professor of Social 
and Community Psychiatry, University College London). Other members are Dr Tom Barker 
(Oxford NHS Foundation Trust), Dr Stephen Bremner (Senior Lecturer in Medical Statistics, 
Brighton & Sussex Medical School), Terry Harper (independent PPI representative, current 
mental health service user) and Paul Stevens (Peer Support Worker, Worcestershire Health 
and Care NHS Trust). Any changes in PSC membership will be reported to the funder, study 
sponsor, PCTU and REC. Minutes of PSC meetings will be placed in the TMF, and reported 
to the funder, study sponsor and PCTU. 
The CI and the PSC will decide whether to form a Data Monitoring Committee (DMC), whose 
charter will be to identify ethical or safety issues emerging during the NEON Trial. The CI will 
inform the funder, study sponsor, PCTU and REC of a decision to form a DMC and its 
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membership, or will provide a justification if a DMC is not formed. The DMC is the only body 
to have access to unblinded outcome data.  
At 2 months, the study team will review recruitment and retention for all three trials. If 
needed, and with advice from the PSC, the study team will implement low-burden 
contingency plans such as extending the recruitment strategy. Examples would include 
obtaining support from charities in advertising the opportunity to participate.  
Once the analysis of the internal pilot is complete (at 4 months or slightly later), the PSC will 
be presented with information about the fidelity, safety, and recruitment and engagement 
performance of the internal pilot. Safety information will include: 
 Anonymous summaries of all SOEs received, including details of which (if any) were 
classified as being both related to the study and unexpected 
 Anonymous analyses of elements of interview transcripts relating to safety 
The PSC will consider this information, and will decide whether to recommend changes to 
study procedures, whether to invoke remedial measures on recruitment and engagement, 
and whether to take forward data collected through the internal pilot into the full trial. For 
pragmatic trials, the latter is known to be a subjective judgement (110).  
The PSC will also decide whether to invoke specific remedial measure to recruitment and 
engagement. The criterion for invoking these are as follows. Recruitment: at or near 147 
participants recruited within the first 4 months (i.e. 75% of target). Engagement: 90% of 
intervention group participants view one narrative within 48 hours of randomisation.  
Remedial action to take would be decided by the PSC, and identified in collaboration with 
the NEON Trial Management Group (TMG), which is composed of representatives of the 
NEON study research team, LEAP and PCTU. Examples of possible remedial strategies for 
recruitment include reducing the follow-up length to allow longer for recruitment or widening 
recruitment beyond England, Examples of remedial strategies for engagement include the 
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addition of face-to-face facilitation by either researchers or local clinical staff. The analysis 
plan for the NEON Trial will be updated accordingly, and any changes would be summarised 
in the NEON Trial report. 
At 6 months the PSC may again formally review recruitment and engagement, in order to 
decide whether the NEON Trial should continue. The stop/go rule for recruitment will be 
attainment of, or clear trend towards, 206 (70%) of target 294 participants in this period. The 
stop/go rule for engagement will be attainment of, or clear trend towards 80% of participants 
view one narrative within 48 hours of randomisation. There are no stop/go rules for the 
NEON-C or NEON-O trials, but if the NEON Trial is stopped, then these two trials will be 
stopped as well.  
A representative of the study funder will be invited to all PSC meetings. Changes to the 
study considered minor (in the judgement of the PSC chair) will be considered 
implementable immediately. Major changes will be referred to the funder for review before 
implementation.  
Operating procedures for the trials 
Unless otherwise stated, the Standard Operating Procedures of Queen Mary University of 
London Pragmatic Clinical Trials unit will be used for these trials. These include procedures 
for notifying relevant parties of protocol updates. 
Analysis 
The trial statisticians conducting statistical analysis work and the NEON Chief Investigator 
will be blinded in relation to allocation status until the SAP is signed off, all follow up data is 
collected, and data cleaning has occurred. Blinding will be through the use of access control 
lists in the file store used to aggregate data from the NEON Trials.  
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To maintain blinding for any interim reports an independent statistician will prepare any 
information which requires knowledge of treatment allocations or involves data which would 
allow treatment allocations to be determined. 
Statistical significance will be assessed at the 5% level, unless otherwise stated. Participant 
flow through the trial will be summarised in a CONSORT flow diagram (111). 
Internal pilot evaluation for the NEON Trial 
Analysis of the internal pilot of the NEON Trial will evaluate factors negatively affecting the 
fidelity of the NEON Intervention, identify any issues affecting the safety of participants, and 
evaluate the recruitment process for the NEON Trial. These categories have been drawn 
from the ACCEPT acceptance checklist for clinical effectiveness pilot trials (110). These 
have been selected from the broader set of categories in the ACCEPT checklist.  
There are three sources of data for the internal pilot evaluation: (1) anonymous transcripts of 
interviews with up to 30 intervention group participants, (2) system operation logs for the first 
three months of operation of the NEON Intervention (3) logs of the first three months of 
participant flow through the NEON Intervention.  
Factors affecting safety will be identified through an inductive thematic analysis of interview 
data. If analysis work identifies specific events which have occurred for individuals, then the 
procedure for handling these is described in the section on safety event monitoring.  
Fidelity will be evaluated through (1) an inductive thematic analysis of interview data to 
identify factors negatively affecting fidelity (2) a descriptive analysis of system operation logs 
to quantify system downtime and the impact on participants of downtime (e.g. by estimating 
numbers of participants using the system at each period where it became unavailable).  
The recruitment process will be evaluated through the production of an interim CONSORT 
diagram (111) for the internal pilot, and the production of a table summarising recruitment 
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routes used, and for each route identifying number of eligible participants, number of 
participants randomised, cost of recruitment.  
Descriptive analysis for the NEON Trial 
Only participants who have completed baseline measures and been randomised will be 
included in descriptive analyses.  
Demographic and clinical outcomes at baseline will be summarised by treatment group. 
Demographic information will include all items collected on the baseline demographics form 
with age presented as mean (SD) and the remaining categorical variables presented as n 
(%).  Clinical outcomes will include quality of life, as measured by the mean item score of the 
MANSA questionnaire; symptomatology, as measured by the total score of the CORE-10 
questionnaire; hope, as measured by the total score of the Herth Hope Index; 
empowerment, as measured by the mental health confidence scale; and meaning in life as 
measured by the mean item score on the presence and search sub-scales of the Meaning in 
Life questionnaire.  Higher scores indicate better outcomes in all but the CORE-10 
measurement scales.  Normally distributed data will be summarised by mean (SD), non-
normally distributed data will be presented as median (IQR). 
For those in the intervention group, engagement will be summarised as the mean (and 
range) number of times a participant logs into NEON, receives a recovery narrative, and 
provides a narrative feedback. 
Serious adverse events, withdrawals and timing of withdrawals from the trial will be 
summarised as n (%) by treatment group.  
The number (percentage) of missing data on the demographics questionnaire and all clinical 
outcomes at baseline and follow-up time points will be summarised, and possible reasons for 
the missing data described and discussed.  
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Clinical outcomes evaluation  
Only participants who have completed baseline measures and been randomised will be 
included in clinical outcomes analyses. 
Primary outcome analysis for the NEON Trial 
The primary outcome is the mean item score of the MANSA at 52 weeks.  Descriptive 
statistics of mean and median scores with standard deviation and interquartile range will be 
presented by treatment group. Analysis will follow intention-to-treat (ITT) principles. The 
primary analysis will be a linear regression model of outcome at 52 weeks adjusting for 
baseline score and selected demographics.  The results will be presented as adjusted 
difference in score at one-year follow up with associated 95% confidence intervals.   
The missing data mechanism will be assumed to be Missing At Random (112) unless evidence 
of violation is found. Under this assumption missing data for the primary and key secondary 
analyses will be imputed using multiple imputation. The number of datasets generated will 
reflect the percentage of missing data present.  Individual analyses on each imputed dataset 
will be combined using Rubin’s rules (112). The imputation model will account for the 
longitudinal nature of the outcomes, and will include all variables contained in the substantive 
model and auxiliary variables which help to support the MAR assumption. Robustness of 
inferences to the MAR assumption will be explored through sensitivity analysis. 
Secondary outcomes analysis for the NEON Trial 
The secondary outcomes are total scores at 52 weeks of the CORE-10, Herth Hope index, 
Mental Health Confidence Scale, and the mean item score on the presence and search 
subscales of the Meaning in Life questionnaire.  Descriptive statistics of mean and median 
score with standard deviation and interquartile range will be presented by treatment group.  
Analysis will follow ITT principles and be conducted on the imputed dataset. The analysis of 
each outcome will be a linear regression model of outcome at 52 weeks adjusting for 
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baseline score.  The results will be presented as adjusted difference in score at one-year 
follow up with associated 95% confidence intervals.   
The primary analysis will be repeated to include an interaction term between treatment and 
service user type at baseline (primary care service user, secondary care mental health 
service user, no prior mental health service use) to explore any differential treatment effect 
among service user types. 
As a secondary analysis, to investigate differences in intervention effect over time the 
primary outcome will be analysed by a linear mixed model with a random effect for 
participant.  
Where outcomes are identified to be non-normally distributed, appropriate transformation or 
non-parametric analyses will be performed and detailed in the statistical analysis plan.   
Exploratory analysis of the NEON Trial 
Exploratory analysis using the intervention group only will examine: the patterns of 
intervention use; predictors of intervention use; and association of usage with clinical 
outcome. Measures of usage include: the number of stories accessed; and the number of 
complete sets of narrative feedback stories provided.   
Univariate associations between each usage measure and demographic and baseline 
clinical characteristics will be assessed by a Poisson regression model with the usage period 
(defined as the number of days between first and last log in) included as an offset term.   
Linear or non-linear regression, as appropriate, will be used to assess the association of 
each usage measure with the MANSA score at 52 weeks.  
To determine which variables and relationships may be important for consideration in the 
design and analysis of future trials a model selection procedure will be conducted for the 
MANSA score at 52 weeks. 
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Since new narratives will be added to the NEON Intervention during the trial, and since 
retraining will be conducted on the machine learning algorithm used in the matching process, 
then we will explore the possible impact on effect size of adding narratives and re-training 
the algorithm. 
Exploratory analysis of the NEON-C and NEON-O Trials 
An exploratory analysis of outcome measures will be conducted using the same principles 
as for the NEON Trial. A preliminary effect size estimate will be made if recruitment and 
retention rates indicate this is statistically justified. This will support choice of outcome 
measures for a future definitive trial. All reporting will indicate that this was an exploratory 
trial 
Economic evaluation of the NEON Trial 
Only participants who have completed baseline measures and been randomised will be 
included in economic analyses.  
The economic evaluation will evaluate the costs of offering the NEON Intervention. It will 
present results with set-up costs both included (sensitivity analysis) and excluded (base 
case). Expected costs of offering the intervention include (1) developing the software (2) the 
costs of operating the online intervention, (3) the costs for periodically upgrading the 
software and updating narratives and (4) the costs of hosting the software on a server 
(including maintenance costs, server space, technical support and licensing arrangements). 
The impact of receiving the intervention on service costs will also be calculated, using 
service use data collected through the abridged Client Service Receipt Inventory (CSRI).  
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Outcomes 
Quality-adjusted life-years (QALYs) will be calculated by attaching available utility weights to 
the health states generated from the EQ5D-5L, using area under the curve methods with an 
assumption of a linear change between time points. 
Incremental economic analysis 
The economic evaluation has been designed using standard reporting criteria (113).The 
estimation of cost-effectiveness ratios will be carried out using the payer’s perspective (NHS 
England). Incremental cost-effectiveness ratios will be calculated in the event of the 
intervention having higher costs and better outcomes (based on EQ-5D-5L and MANSA). 
Disaggregated costs and outcomes, and both deterministic and probabilistic incremental 
cost effectiveness ratios, will be presented. The base case analysis will incorporate only 
NHS and Personal Social Services (PSS) costs and will express costs incurred in terms of 
QALY gain. Uncertainty will be addressed by generating cost-effectiveness planes from 
bootstrapped resamples. Cost-effectiveness acceptability curves will be constructed to show 
the probability that the intervention is cost-effective for different cost-per QALY thresholds.  
Further sensitivity analysis will examine (separately and together) the effects of: expressing 
incremental changes in cost in terms of changes in MANSA; incorporating lost work; 
including intervention set-up costs; and variability in service delivery and uptake as 
determined during the RCT and process evaluation. Given the expected attrition of service 
user response, standard multiple imputation approaches to missingness will be employed 
and the effects on cost effectiveness estimates will be examined. 
Process evaluation analysis 
Process evaluation analysis for the NEON Trial will follow best practice guidance (114, 115). 
It will consider fidelity, reach, dose and adherence, and acceptability for the NEON 
Intervention. It will also evaluate the NEON change model for the study population, and 
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identify any safety issues relevant to future use of the NEON Intervention. Analysis will 
integrate quantitative data collected electronically through the NEON Intervention and 
qualitative data collected through interviews with three groups (withdrawal of consent, 
intervention, low engagers). Across all process evaluation analysis work, a particular focus 
will be on understanding the experience of participants who have never used mental health 
services, to generate knowledge about usage of the intervention by a large and under-
researched group. This will amount to a planned sub-group analysis of all participants who 
self-identify as a member of this group through the Trial demographics form. Process 
evaluation analysis for the NEON-O Trial and NEON-C Trial will be much more limited, and 
will primarily focus on acceptability, through the analysis of qualitative interview data and 
logged intervention usage data. 
Fidelity 
We will evaluate factors that enabled or blocked usage of the NEON Intervention as a 
technology for delivering recorded recovery narratives. This will include quantitative analyses 
of logging data to identify periods of up- and down-time for the NEON Intervention and the 
implications of participation for down time, and the identification of factors enabling or 
blocking usage through interview analysis, such as difficulties obtaining access to computers 
or networks as a form of digital exclusion (116).  
Reach 
The reach of the NEON Trial will be investigated by analysing sociodemographic, clinical 
and geographic characteristics of participants to consider representativeness. For example, 
the sociodemographic profile of participants will be investigated to identify if there are groups 
who would be expected to but are not accessing the intervention, supplemented by 
qualitative data revealing any specific problems with accessibility.  
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Dose and adherence 
There is no desired ‘dose’ of recovery narratives received, or no desired pattern of 
adherence to treatment, as even just receiving one recovery narrative might produce life-
changing results. Rather, since no definitive trial of the use of recorded recovery narratives 
in the treatment of psychosis has been conducted, the aim of this part of the process 
evaluation will be to provide an understanding of patterns of receiving recovery narratives, 
and to explore their relationship to outcomes. This will support future clinical and non-clinical 
use of the NEON Intervention.   
To provide an understanding of how the intervention was used, summary statistics will be 
presented for intervention use using data collected in the NEON Intervention logs. Duration 
of engagement will be calculated as number of days from baseline to final narrative received 
for each participant. Number of recovery narratives accessed per week of the intervention 
will be calculated using completion of all three narrative feedback questions as an indicator 
that the narrative has been processed in full. Summary statistics showing number of 
recovery narratives accessed in total versus number of recovery narratives accessed and 
feedback provided for will be presented.  
Acceptability 
The acceptability of the intervention will be evaluated through a deductive analysis of 
interview data. This will utilise existing frameworks (117) to structure transcript fragments. 
Evaluation of the NEON change model 
The NEON change model will be evaluated through qualitative analysis of interview data. 
Thematic analysis will be applied, using a hybrid deductive-inductive approach. An initial 
coding framework will be produced using concepts named in the trial change model, and this 
will be extended inductively by application to interview data, to allow for unanticipated forms 
of change to be accounted for. Analysis will be supplemented by consideration of 
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quantitative data, e.g. the extent to which high connection was associated with high hope-
promotion, as assessed using narrative feedback scores. 
Safety of the NEON Intervention 
Factor relating to the safety of the NEON Intervention will be evaluated through qualitative 
analysis of interview data. Thematic analysis will be applied, using a hybrid deductive-
inductive approach. This will begin with codes relating to safety developed through the 
qualitative analysis of the internal pilot (if any), which will be extended inductively through 
application to interview data.  
Evaluation of the supervised machine learning algorithm 
The performance of the selected supervised machine learning algorithm in training a model 
to do content-based recommendation will be evaluated, led by Jeroen Keppens, a machine 
learning expert who is an investigator on the NEON study. Firstly, models used by the 
algorithm during the NEON Trial will be inspected and described, providing information about 
types of matching data that were influential / not influential in the NEON Trial matching 
process. The generalisations generated by the model will be compared against first-
principles by examining whether they fit the domain literature and patterns observed by 
mental health researchers in this study. 
The performance of supervised machine learning algorithm will be evaluated by comparing 
its performance to that of a range of standard supervised machine learning algorithms 
suitable for recommendation systems. To enable this comparison, and to ensure that the 
evaluation assesses how well each algorithm generalises to unseen data, all available 
recovery narrative feedback data generated during the NEON Trial will be partitioned into a 
training dataset and a validation dataset.  This process is repeated over different partitions of 
the dataset into training and validation datasets (118).  
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The performance evaluation of each algorithm will utilise a vector metric calculated from 
logged narrative feedback data.  Better algorithms will be defined as those that recommend 
narratives that score highly on one or more of these criteria.  To assess the quality of a 
model produced by a machine learning algorithm, standard assessments of precision and 
recall in reproducing a top-N of narratives will be employed (119). 
Discussion 
Approaches to reducing bias 
The following approaches to reducing bias in clinical trials (120) have been adopted for all 
three trials. 
Selection bias 
To minimise baseline differences between groups, all participants will be randomly allocated 
using an allocation algorithm validated by the overseeing Pragmatic Clinical Trials Unit 
(PCTU). 
Detection bias 
To eliminate any differences in how outcomes are measured, all participants will only provide 
outcome data through an online interface, which will be identical for each group. 
Attrition bias 
To reduce differences in attrition between the control and intervention group, control group 
participants will be told that they will receive access to the NEON Intervention after the 
primary endpoint, and all participants will be compensated for the time and effort of providing 
outcome data.  
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Reporting bias 
ISRTCNs have been registered for all three trials, the trial report will be published open 
access, and a summary of trial results will be provided on the NEON study website.  
Contamination bias 
To avoid contamination through being allocated to the Intervention group in one trial and the 
control group in another, individuals will only be allowed to take part in one trial.  
Contamination is otherwise possible in three ways: 
a) A participant allocated to the control group could repeatedly register until allocated to the 
intervention group. This will be minimised by not allowing the creation of a new login 
using the same email address as an existing login. 
b) A participant allocated to the control group could request and use the login details from 
an intervention group participant. This risk is low because recruitment is online so 
participants will not generally know who else is participating. This will be further 
minimised by asking all participants not to share their login details. 
c) Deciding to participate in the trial might prompt participants to access publicly available 
narrative repositories (e.g. YouTube), or a participant may receive narratives through 
clinical care (e.g. from a peer support worker). To monitor this form of contamination, all 
participants will be asked at follow-up about access to recovery narratives outside of the 
NEON Intervention. 
Support for safe interaction with the NEON Intervention 
A broad range of measures have been incorporated into the design of the NEON 
Intervention and the study procedures for the three trials to enable safe usage. These 
approaches have been developed in consultation with the NEON LEAP and NEON 
International Advisory Board (IAB).  
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1. Potential participants will be informed through the participant information sheet about 
forms of harm that can be caused by receiving recovery narratives, to enable an 
informed choice about participation. This information draws on the results of research 
conducted by the NEON study (4, 5). It will provide participants with knowledge to 
support self-management.  
2. All narratives used in the NEON Intervention will first be characterised by researchers, 
using the Inventory of Recovery Narrative Characteristics, which has been developed by 
the NEON team This includes items to identify narratives which should have content 
warning(s) about potentially distressing content. For the NEON trials, the characteristics 
of each narrative included in the NEON Intervention will be rated by a single researcher 
using INCRESE. Additionally, since our testing indicates that it is not possible to identify 
narratives requiring content warning with 100% accuracy because of differences in rater 
interpretation about content, items relating to content warnings will be second-rated by a 
separate rater. If either rater identifies a content warning as relevant, it will be applied. 
Narratives including distressing content should not be excluded, as content which is 
distressing for some will provide benefits to others (5).  
3. The Initial Information Page, which is the first page encountered in the NEON 
Intervention, will enable intervention group participants to specify categories of 
potentially distressing content that they wish to avoid, and this preference can be 
updated through the About me page. Narratives identified by raters as including that 
content will never be visible to participants. Being able to exclude all narratives including 
a particular type of content is a form of self-management.  
4. If a narrative is identified as including a type of potentially distressing content which has 
not been excluded by a participant, then before the participant accesses this narrative, 
they will be shown a content warning, and given the choice of whether to continue or not. 
5. Users can block a narrative that they find distressing, and this narrative will not be listed 
in the NEON Intervention until unblocked 
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6. Self-management strategies identified by participants at first login are shown to them 
when they click the I’m upset button 
7. At first login, the Useful Information page will provide brief advice on how to handle 
difficult emotional responses to narratives, and further advice will be provided on the ‘I’m 
upset’ page. This information will always be available through the footer of the NEON 
Intervention.  
8. A button labelled ‘Get me out of here’ is provided in case a participant feels distressed 
and wants to quickly close the interface, or if the interface is being accessed in a public 
setting and a participant does not want others to know about their usage.  
9. Topic guides of interviews with the internal pilot, intervention and low-engagement 
groups will consider safety issues, and analysis of interviews allows the opportunity to 
refine the NEON Intervention or trial processes in light of unanticipated safety issues.  
Our decision to use content warnings (also known as trigger warnings) has drawn on a 
review of the literature on content warnings, conducted through systematic searches of the 
MEDLINE, CINAHL and PsycINFO. These have identified four publications presenting 
empirical evidence on the impact of real-world usage of content warnings. These studies 
show that content warnings can reduce harm by reducing stress in students with PTSD 
diagnoses (121) and by reducing negative emotions produced by engaging material (122). 
They can be useful if provided well in advance of discussions in an educational context 
(123), and can reduce negative emotions and signal supportive environments, which may 
promote engagement with otherwise distressing material in the long run (122). They can 
however also increase avoidance, which may prevent people from learning to cope with 
distressing content (122). Only one randomised controlled trial has been conducted 
examining the psychological effects of issuing content warnings (124). This trial found that 
warnings produced a small increase in self-reported anxiety after reading potentially 
disturbing literary passages amongst people who believed words can cause harm. It also 
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found a slightly increased perceived risk of suffering long-term emotional harm in the wake 
of a traumatic event. 
Safety of narrative donors 
The NEON Intervention presents recovery narratives from the NEON Collection. A protocol 
for the management of the NEON Collection was previously approved by the UK Health 
Research Authority. The IRAS ID for this approval is 24734. The protocol was given 
favourable opinion by the West London & GTAC Research Ethics Committee. The REC 
reference is 18/LO/0991. This approved protocol supports the safety of individuals whose 
narratives are incorporated in the NEON Collection in the following ways: 
 Narratives are only included in the NEON Collection where valid consent has been 
documented. Narratives sourced from public collections are only included if the narrator 
has provided his/her publisher with consent for public reuse, or if the narrator has been 
approached and provided explicit consent for use in the NEON Collection. Where a 
narrative is donated directly to the NEON Collection, then informed consent is provided 
through an online consent form. Narrators can withdraw consent for inclusion whilst the 
NEON Collection is in use. 
 Narratives are incorporated exactly as originally published.  
 All candidate narratives are assessed by at least one researcher against inclusion and 
exclusion criteria published at http://researchintorecovery.com/neoncollection. If eligibility 
is unclear, then a final decision is made by a Collection Steering Group consisting of four 
members of the LEAP and two researchers. 
 Third-parties can request withdrawal of a narrative, e.g. if a narrator has died, or if they 
assert that the narrator did not have capacity to consent to inclusion of their narrative. 
They do not have an automatic right to withdrawal, in order to protect the rights of the 
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narrator to have their story told. A final decision on third-party requests is made by the 
Collection Steering Group. 
These strategies were developed with advice from the LEAP. Three members of this panel 
have published their own recovery narratives. 
Trial status 
The current version of the trial protocol is v4.0. 16.01.20 
The trial opened to recruitment on 9.3.20. Planned recruitment close is 30.4.21. Planned trial 
end is 30.4.22.  
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Tables 
Table 1 Outcome measures used in the clinical outcomes analysis.  
‘x’ indicates a timepoint where measures are collected, bold text indicates primary endpoint 
Domain Measure  Items Report Timepoint 
(week) 
    0 1 12 52 
Quality of 
life 
Manchester short 
assessment of 
quality of life 
12 Mean item score. 
Range: 1-7. 
Higher better. 
x x x x 
Symptoma
tology  
CORE-10 10 Total item score. 
Range: 0-40.  
Lower better. 
x   x 
Hope Herth Hope Index 12 Total item score. 
Range: 4-48. 
Higher better. 
x   x 
Empower
ment 
Mental Health  
Confidence Scale 
16 Total item score. 
Range: 16-96  
Higher better. 
x   x 
Meaning 
in life 
Meaning in Life 
Questionnaire 
10 Mean item score for 
presence and search 
subscales. Range: 1-7. 
Higher better.  
x   x 
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Total: 60 items 
 
Table 2 Health economics measures 
‘x’ indicates a timepoint where measures are collected 
Domain Measure  Items Timepoint 
(week) 
   0 1 12 52 
Health-related 
quality of life 
EQ5D-5L 5 x   x 
Service use Client Service Receipt Inventory (abridged). 
6-month retrospective at baseline, 12 months 
retrospective at primary endpoint.  
10 x   x 
 
Table 3 Online questions used to establish eligibility and log information about recruitment  
Question Eligibility decision and next question  
Q1: How did you find out about the NEON trials? 
[Though my family doctor or GP surgery, 
Through a hospital or mental health service, 
Other] 
Through a hospital or mental health 
service: Go to Q2 
All other options: Go to Q3 
Q2: Was this through any of the following trusts? 
[List of current secondary care research sites, 
None of these] 
Go to Q3 
Q3: Are you 18 or over today, and normally 
resident in England? [Yes / No] 
Yes: go to question Q4 
No: not eligible for any trial.  
Q4: Can you understand written and spoken 
English? 
 
Yes: go to Q5 
No: not eligible for any trial.  
Q5: Within the last 6 months, have you had 
mental health problems that: 
a. make it hard to manage the day-to-day 
demands of life? (No, A bit, Yes) 
b. currently cause you emotional distress? (No, 
A bit, Yes) 
c. cause you social problems like loneliness (No, 
A bit, Yes) 
No to all sub-questions: go to Q7 
Otherwise: go to Q6 
 
Q6: In the last five years have you had 
experiences diagnosed as psychosis, or that 
Yes: eligible for NEON Trial.  
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you or others would call psychosis (such as 
seeing or hearing things that others have not, or 
having unusual beliefs that other people 
disagree with)? [Yes / No] 
No: eligible for the NEON-O trial.  
 
Q7: Within the last five years, have you cared 
for someone with experience of mental health 
problems? 
Yes: go to Q8 
No: not eligible for any trial.  
Q8: Was this as part of your employment or 
profession? 
Yes: not eligible for any trial.  
No: eligible for the NEON-C trial.  
 
Table 4 Logs of participant system usage to collect 
Event to log Information logged 
Potential participants completes first question 
of eligibility checking process 
PPID, DATETIME 
Potential participant completes eligibility 
checking process 
PPID, How Found, Research site, 
Allocated trial, Q5 responses, 
DATETIME 
Potential participant expands or collapses item 
in the PIS 
PPID, PIS item number, PIS action, 
Allocated trial, DATETIME 
Potential participant navigates up or down 
through the PIS 
PPID, PIS action, Allocated trial, 
DATETIME 
Potential participant makes decision about 
participation 
PPID, Participation decision, 
Allocated trial, DATETIME 
Potential participant completes ICF PPID, Participation decision, 
Allocated Trial, Process evaluation 
invitation, DATETIME 
Validation email sent PPID, DATETIME 
Participant confirms participation by clicking 
link in validation email  
PPID, PID, DATETIME 
Participant receives blank 
demographics/measures form 
PID, Form name, DATETIME 
Participant submits complete 
demographics/measures form 
PID, Form name, Form items, 
DATETIME 
Participant randomised  PID, Allocated Trial, Allocated group, 
DATETIME 
Participant logs in to NEON Intervention PID, SID, Access device, 
DATETIME 
Participant shown recovery narrative PID, SID, NID, RID, Route to 
Access, Categories, DATETIME 
Participant provides narrative feedback  RID, Narrative feedback, DATETIME 
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Participant logs out of NEON Intervention SID, DATETIME 
Participant sent reminder about the NEON 
intervention 
PID, Reminder Communication 
Mechanism, DATETIME 
Participant changes information on About Me 
page 
PID, About Me, DATETIME 
Participant requests payment of a voucher PID, DATETIME 
Participant selects button in footer PID, Button name, RID (null if 
narrative not being viewed), 
DATETIME 
Participant navigates to external URL PID, URL, DATETIME 
Participant confirms withdrawal request PID, DATETIME 
Participant blocks narrative PID, NID, DATETIME 
Participant bookmarks narrative PID, NID, DATETIME 
Participant unblocks narratives PID, DATETIME 
Non-participant safety event reporting form 
submitted 
Safety event type, Caused by study,  
Date of event, Location of event, All 
other text on form, DATETIME 
Participant safety event reporting form 
submitted 
PID, Safety event type, Caused by 
study, Date of event, Location of 
event, All other text on form 
DATETIME 
 
Table 5 Logs of system operation 
Item Information logged 
Heartbeat DATETIME  
Planned system close down DATETIME  
Planned system restart DATETIME  
Unplanned system restart DATETIME 
Model retrained DATETIME, Parameters 
Narrative batch added DATETIME, Narratives 
Details of additional files 
File name File 
format  
Title of data Description of data 
Additional File 1 PDF  Items in the NEON Intervention personal 
profile 
Defines all items 
included in the 
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personal profile for 
each NEON 
Intervention user. 
Additional File 2 PDF 
  
Demographics and measures forms Defines all online 
demographics and 
measures forms used 
in the NEON Trials.  
Additional File 3 PDF  Promotional principles  Defines principles to 
which all promotional 
messaging for the 
NEON trials must 
conform. 
Additional File 4 PDF  Recruitment poster for all NEON trials.  Integrated recruitment 
poster to promote all 
trials.  
Additional File 5 PDF  Recruitment poster for the NEON Trial Recruitment poster 
specific to the NEON 
Trial. 
Additional File 6 PDF  Recruitment poster for the NEON-C Trial Recruitment poster 
specific to the NEON-
C Trial. 
Additional File 7 PDF  Recruitment poster for the NEON-O Trial Recruitment poster 
specific to the NEON-
O Trial. 
Additional File 8 PDF  Participant messaging in the NEON trials Defines messages 
displayed to 
participants in the 
NEON trials. 
Additional File 9 PDF Online Participant Information Sheet  Text and layout for the 
online Participant 
Information Sheet 
used in the NEON 
trials. 
Additional File 10 PDF  Online Informed Consent Form Text and layout for the 
online Informed 
Consent Form used in 
the NEON trials. 
Additional File 11 PDF Process evaluation Informed Consent 
Form 
Paper Informed 
Consent Form for use 
in process evaluation 
interviews.  
Additional File 12 PDF  Process evaluation topic guide Topic guide for 
process evaluation 
interviews. 
Additional File 13 PDF  Safety event reporting forms  Defines questions 
used in two safety 
reporting forms. 
 
